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Abstract  
Background Supraventricular tachycardia (SVT) is a relatively common 
condition causing palpitations, which, if not treated, can have serious adverse 
effects. SVT can initially be treated with a Valsalva manoeuvre (VM) (an 
exhalation against resistance, similar to blowing up a balloon), which induces a 
vagal response (drop in heart rate), terminating SVT in 5-54%. The VM’s efficacy 
is variable and there is debate as to the best way of generating the strain in 
practice and in which posture the VM should be carried out. A purpose-built 
device (Valsalva Assist Device (VAD)) has been proposed to improve this. We 
aimed to compare vagal responses of the supine and modified posture VMs using 
the VAD and standardised manometer. 
 
Methods We performed a repeated measures randomised trial of four VMs (two 
supine VM and two modified VMs) in healthy adult volunteers with strains 
delivered using a manometer or VAD. Changes in heart rate were compared 
between the techniques. The pressure and duration of VM strains achieved with 
the VAD and manometer and adverse events were recorded and compared. The 
trial was registered with ClinicalTrials.gov (NCT03298880) and approved by the 
University of Exeter Medical School Ethics Committee. 
 
Results 75 healthy participants aged 19-55 were recruited over three months. A 
mixed-effects linear regression was completed showing the modified VM had a 
significant drop of 7.7 bpm compared to the supine VM (p<0.001, CI 5.6 to 9.8). 
The VAD produced similar strain pressures but slightly shorter duration strains 
compared to the manometer. 
 
Conclusions Modified VM was associated with a greater drop in heart rate than 
a supine VM. The VAD can be used to safely generate the recommended VM 
strain with equivalent pressure to the manometer but may require modification to 
enable the recommended duration of strain and full effect to be achieved.  
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Introduction  
The Valsalva Manoeuvre (VM) is a safe, internationally recommended, first-line 
treatment for hemodynamically stable supraventricular tachycardia (SVT). (1,2) 
The VM is a simple technique of forced exhalation against resistance (similar to 
blowing up a balloon), which causes a reduction in heart rate mediated through 
the vagus nerve. Its success rate in clinical practice is variable (5-43%) with a 
very safe side effect profile. Achieving the best cardioversion rate possible is 
important as the usual second-line treatment (adenosine) typically requires 
hospital attendance, has significant side effects and is disliked by patients. (2,3) 
Adenosine pauses the heart and creates a sense of impending doom in the 
patients. (4) 
 
The highest cardioversion rate achieved in clinical practice to date used a 
manometer controlled (40mmHg) strain and a modified VM (post strain leg 
elevation and supine positioning). However, the physiological advantage of this 
modification over a supine VM (currently the gold standard) has not been studied. 
VMs in clinical practice are often done incorrectly and usual methods of strain, 
such as using a syringe, are unreliable. (5) This is due to incorrect pressures 
being produced, which may not be as effective in activating the vagus nerve.  
 
A purpose designed Valsalva assist device (VAD) would ensure a correct strain 
pressure is used, could carry instructions for the modified VM and could be kept 
by patients for immediate use should an attack recur. Evidence suggests that the 
earlier a VM is carried out, the more effective it is. (6) A VAD has recently been 
developed by Meditech and Andrew Appelboam but has not yet been tested in 
healthy volunteers. 
 
We determined the efficacy of the modified VM and the VAD, by measuring their 
vagal response (decrease in heart rate) in healthy volunteers.  
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Aims and Objectives 
Aims: 
 This study aims to determine the physiological effects of a modified VM 
and evaluate the performance of a novel Valsalva assist device in 
healthy volunteers. 
 
Objectives: 
 To undertake a literature review answering three questions 
o What is the most effective type of VM? 
o How effective is the VM in terminating SVT? 
o How effective are current methods for strain creation? 
 
 To evaluate whether there is a difference in vagal tone (drop in heart 
rate) in healthy volunteers performing a modified VM versus a standard 
supine VM. 
 To evaluate the differences in vagal tone created by the VAD compared 
to the manometer. 
 To measure and compare peak strain pressure and duration produced 
using the VAD compared to a standard manometer in supine and 
modified position. 
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Chapter One - Overview of Supraventricular Tachycardia 
and the Valsalva Manoeuvre 
Supraventricular Tachycardia (SVT)  
SVT is a disorder of the heart causing a substantial increase in heart rate due to 
the rapid generation of electrical impulses. This is caused by a small area of 
tissue or a distorted conduction pathway which creates an electrical circuit, often 
these involve re-entrant electrical activity. (7,8). These accessory pathways 
usually involve the atrioventricular node; this node is significantly affected by the 
autonomic nervous systems. (8) The incidence of SVT in America is 35/100,000 
and is responsible for 50,000 emergency department visits annually showing that 
it is relatively common. It can also be a disabling condition. (9,10) These 
palpitations can be extremely distressing for patients, especially if they are 
experiencing them for the first time.  SVT is a common presentation to ED, with 
an average of 50-100 patients per year in each UK emergency department (2) 
There is no standardised heart rate for the diagnosis of SVT as some people 
have SVT with a heart rate as low as 75, and the condition is diagnosed using an 
ECG. (11,7)  
 
There are various types of SVT – Sinus Tachycardia, Atrioventricular Nodal Re-
entry Tachycardia (AVNRT), Atrioventricular Re-entry Tachycardia (AVRT), Atrial 
Tachycardia, Atrial Flutter, Atrial Fibrillation, Inappropriate Sinus Tachycardia, 
Sinus Node Re-entry, Permanent Junctional Reciprocating Tachycardia, Non-
paroxysmal Junctional Tachycardia, and Focal Junctional Tachycardia. (7) 
However, in practice, the term SVT is most often used to describe the more 
common Re-entry Tachycardia’s AVNRT, AVRT and Atrial Tachycardia. Atrial 
Fibrillation and Flutter tend to be distinct diagnoses as they have more 
characteristic ECG features, do not respond to vagal manoeuvres and have 
different treatments. (12) This practical approach to the term will also apply in this 
dissertation.   
 
  
  
13 
  
Aetiology of SVT 
Whilst some risk factors have been identified the underlying aetiology has not 
been identified. It has been shown that peak incidence of SVT presentation is in 
the middle decades of life (AVNRT at 48 range 30-66) years, AVRT at 36 (18-
64). (13) SVT presents as palpitations and can cause a great decrease in a 
patient’s quality of life. (7)   
 
Types of SVT 
Atrioventricular Nodal Re-entry Tachycardia (AVNRT)  
AVNRT is a re-entrant circuit which travels through the posterior and anterior 
conduction pathways into the atrioventricular node (AV node). 25% of the 
population has two pathways inputting to the atrioventricular node, a fast 
conduction pathway and a slow conduction pathway. These two pathways form 
the re-entrant circuit. (7) SVT starts with an extrasystole (premature beat), during 
the refractory phase of the fast conduction pathway, causing the impulse to be 
conducted through the slow pathway. This impulse reaches the distal end of the 
tissue, where the fast pathway is ready to receive the impulse, so it conducts the 
impulse backwards (retrograde), now the proximal part of the slow pathway is 
repolarised (due to short refractory period) and can be stimulated again. This is 
how the circuit starts and the impulses continue round the short and fast pathway 
creating the typical re-entrant circuit. (14) The atypical re-entrant circuit is formed 
when the impulse travels in the opposite direction. These differences are 
demonstrated in different ECG morphology; typical AVNRT has invisible p waves 
as they are hidden within the QRS complex, where atypical AVNRT produces 
inverted p waves typically in the middle of or late in the RR interval. (7) 
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Figure 1 Mechanism for Atrioventricular Nodal Re-entry Tachycardia (7) 
 
Atrioventricular Re-entry Tachycardia (AVRT) (including Wolff-Parkinson-White 
syndrome) 
This re-entrant pathway requires the presence of an accessory pathway; this is a 
small strand of myocardium that bridges the atrioventricular insulation, which 
causes pre excitation of the ventricle as it is conducted more rapidly through this 
section than through the AV node. (15) This early ventricular activation manifests 
as a delta wave (upstroke in the QRS complex), however this is not always 
present. (7,16) These pathways can conduct in both directions, and the pre-
excitation varies depending on the time required to cross the AV node and 
location of the accessory pathway. Differing from the AVNRT this arrhythmia is 
triggered by an extra atrial systole (premature beat from atria) that finds the 
accessory pathway refractory due to the normal impulse having just been 
conducted. Therefore, the impulse is transmitted down the AV node and then up 
the accessory pathway. This is where the circuit starts and continues as the 
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impulse is transmitted from the accessory pathway to the AV node continously. 
(7)  
 
Atrial Tachycardia 
Atrial tachycardia is the result of an abnormal impulse formation or re-entrant 
mechanism. These are usually classified by their origin within the atrium, e.g. 
focal atrial tachycardia or macro re-entry. (7) It can be hard to distinguish atrial 
tachycardia from other types of SVT on standard ECG investigation. This causes 
these rhythms to be commonly managed in the same way at least initially, in the 
emergency department (ED). Due to the low proportion of atrial tachycardia in 
SVT, there is little reason to distinguish it quickly in ED. (2)  
 
Figure 2 Mechanism for Atrioventricular Re-entry Tachycardia (7) 
 
The current first line treatment for terminating SVT is the Valsalva manoeuvre. I 
will discuss this manoeuvre below. 
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Valsalva Manoeuvre 
The first line treatment of SVT is the VM. The Valsalva manoeuvre (VM) is a short 
(15 seconds) strain similar to that of bearing down or blowing up a balloon, which 
increase intrathoracic pressure (40mmHg). This in turn causes a complex 
physiological reactions resulting in a rise in blood pressure and a drop in heart 
rate; it can also give important diagnostic information in the case of atrial 
tachycardia (exposing p wave morphology). (17,7,2)  It is inferred that those VMs 
that produce the most significant fall in heart rate have the largest vagal tone and 
will therefore have the highest chance of conversion from SVT to sinus rhythm. 
(8)  
 
The 40mmHg strain for 15 seconds is the simplest VM and is currently standard 
practice; it is achieved by blowing into a standard manometer or syringe in the 
supine position. This method of creating the VM is the NICE recommended first-
line treatment for SVT. (17) Using the most effective method of VM is essential, 
to increase the chances of a successful termination of SVT and reduce the need 
for other interventions. (18) The optimal technique has been debated, and 
different techniques trialled to find the best. Recent studies have demonstrated 
that a postural modification of the VM has a better outcome for terminating SVT.  
(18) This technique is termed the modified VM. This is where a patient carries out 
the Valsalva strain for 15 seconds at 40mmHg in a semi-recumbent position (45-
degree angle). Immediately at the end of the strain, they are laid flat and have 
their legs raised at 45-degrees for 15 seconds before returning to a semi-
recumbent position as shown in figure 3. (2) 
 
 
 
 
 
 
Figure 3 The Modified VM (19) 
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The VM is one of the best treatments available because it is inexpensive, non-
invasive and easily reproducible with minimal side effects. (20) The use of VM 
has been shown to reduce complications of drug therapy without changing the 
number of treatment failures. (3) It is shown to be frequently effective in the 
termination of SVT, and if immediately undertaken can prevent the need for 
hospital admission. (8)  
 
History of VM  
There is some controversy about the origin of the VM, but it is thought to be first 
described by Antonio Valsalva in 1704, in Italy. (21) Its earliest description 
involved occluding mouth and nostrils as the air was compressed inwardly, it was 
claimed to expel pus from the middle ear.  Valsalva postulated that this procedure 
would cause the expulsion of abnormal cerebral matter either via the wound, 
mouth or the auditory meatus. (21) This he believed possible due to the presence 
of a foramina between the ear and the cranial cavity. However, there is some 
controversy whether this is the first definition of a VM, as in 1497 Leonard of 
Bertapaglia described a similar phenomenon thought to be able to detect skull 
fractures. (22)  
 
There are also hints of the origin of vagal manoeuvres in ancient Egyptian healing 
practices, though this has not been proven. The VM was largely forgotten until 
1859 when Weber showed the VM was able to interrupt his pulse. However, his 
experimentation was stopped when he developed convulsions while 
demonstrating this manoeuvre to a crowd. (23) This was probably an early 
illustration of the risks involved in prolonged reduction in venous return, causing 
cerebral hypoxia. (24) In 1913 it was proposed that stimulating the vagus nerve 
by pressure, e.g. carotid sinus massage would terminate the paroxysmal 
tachycardia.  (25) Cohn reviewed the evidence for the efficacy of vagal 
manoeuvres in 1913 and found it was mixed and viewed with mistrust. Cohn 
stated that while carotid sinus massage was effective, another manoeuvre 
seemed to be more effective, this he described as a deep respiratory movement 
which we are led to believe is a VM. (25) The evidence shows that using vagal 
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stimulation to terminate tachycardia has been around for a long time, though its 
use has never been widespread before due to its lack of efficacy.  
 
Uses of VM 
The VM has been used for a variety of different reasons, most commonly for 
termination of SVT, assessment of heart disease and autonomic nervous system 
functionality. (20) In cardiology and urology, it can be used diagnostically in 
conjunction with other examinations, to assess heart failure and incontinence. 
(26)  Heart failure is assessed in two ways either using a doppler or by assessing 
the heart rate response during a VM. There is no tachycardia during the strain 
phase of the VM in heart failure; ventricular rigidity means that changes in preload 
do not affect the stroke volume, causing no change in heart rate. (26) The VM is 
used to assess the extreme values of intrastrain tachycardia and post strain 
bradycardia, which is used to quantify autonomic nervous system failure. (27,28) 
This is important as these conditions can affect the efficacy and safety of the VM 
in terminating SVT.  
 
Although the most common use of the VM is the management of supraventricular 
tachycardia, variations are used by other specialities.  ENT specialists use a form 
of VM against a closed glottis (to test Eustachian tube function) which does not 
raise intrathoracic pressure so, therefore, it is not a true VM. (28,29)  
 
Physiological Effects of VM   
To understand why the VM is effective at terminating SVT, we must first explore 
the physiology underlying the VM. The most critical physiological effect is the 
bradycardic response. (30) In the past, there has been controversy about the 
physiological effects caused by the VM. This reflects the complex mechanisms 
involved in the physiology of the VM. (30,22) This intricate process includes a 
hemodynamic and autonomic response which can be divided into five phases. 
(30) 
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Phase zero is the intake of breath before the VM and is therefore sometimes not 
included. This breath causes an initial decrease in intrathoracic pressure, causing 
a compensatory fall in arterial pressure. (30) 
 
Phase one is the onset of the strain, where the pressure of the thorax is increased 
causing a rise in blood pressure and causes a transient slowing of the heart rate. 
This is due to the intrathoracic pressure causing a direct mechanical effect on the 
heart and intrathoracic blood vessels. (31,30)  
 
Phase two is the end of the strain, where the pressure in the abdomen and thorax 
rises causing a significant decrease in venous return, and therefore reducing left 
ventricular preload, causing a consequential decrease in stroke volume resulting 
in a drop in blood pressure. (32) This causes a reflex rise in heart rate and 
peripheral vascular resistance taking place about 7 seconds into the strain, which 
gradually brings the blood pressure back to baseline, due to this increased 
sympathetic activity. (28,30) 
 
Phase three is the release of the strain causing a decrease in intrathoracic 
pressure leading to an instant drop in blood pressure. However venous return is 
recovered and blood flow increases, improving diastolic filling and stroke volume. 
This increased stroke volume is pumped into the increased vascular resistance 
(vasoconstricted vessels) causing a spike in blood pressure. (31,30)  
 
Phase four shows the blood pressure overshoot, triggering the carotid sinus 
receptors reflex, which excites the vagal nerve increasing vagal tone causing a 
decrease in heart rate, although the blood pressure remains high for some time 
this is thought to be due to adrenal medulla hormones, as the sympathetic nerve 
activity is low. (28,30,31,33,27,26)    
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Previous studies have shown that increasing the refractoriness of the AV node 
with vagal stimulation can terminate SVT. It was shown that the response rate 
was related to the level of vagal reaction. (34) 
 
Physiological Effects of Modified VMs 
There have been various attempts to modify the VM over the years to increase 
its utility in everyday practice. This section will review the physiology behind the 
supine VM, Trendelenburg VM, erect VM, sitting VM, semi recumbent VM and 
the modified VM. 
 
Currently, the gold standard VM is the supine position; this is thought to be better 
due to increasing a patients’ vagal tone and reducing the sympathetic response. 
Increasing venous return during phase four will increase the vagal response 
causing a more significant bradycardic effect. (35) A recent study done in children 
with SVT examined a modification to induce a more significant vagal response. 
The technique assessed patients that were turned upside down or did 
headstands and showed a cardioversion rate of 67% vs 33% compared to 
standard VM on the first attempt. This supports the evidence behind the idea that 
increasing the venous return increases the vagal tone and rate of cardioversion. 
(6) 
 
The Trendelenburg VM is when a patient lies supine with their head tilted down 
10-15 degrees. The Trendelenburg modification was thought to work on a similar 
principle as the supine VM that the head down position would increase vagal tone 
increasing the bradycardic response, however it has not been shown to be an 
improvement. (35,18)  
 
The erect position (standing) of the VM is much less effective compared to the 
supine VM and is thought to be due to raised sympathetic tone blunting 
baroreflexes. (36,37) This study showed that the heart rate increased with 
increased orthostatic pressure due to the fall in blood pressure, this reduces 
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conduction to the glossopharyngeal and vagal nerve. This occurs in conjunction 
with the activation of the adrenergic system, leading to increased vascular 
resistance. This causes a beta blockade, which blunts the baroreflexes, resulting 
a decrease in vagal nerve stimulation.  
 
Other positions which have been reviewed are the semi-recumbent position and 
sitting position. Both of these have been shown to be less effective than supine 
VM. (8) This is thought to be due to blood pooling in the legs causing larger basal 
sympathetic tone, causing a reduced vagal response. The surge in venous return 
that precipitates the vagal response is also diminished due to gravitational forces 
in sitting and semi-recumbent positions. It is important to know that the supine 
position was significantly more effective compared to the semi-recumbent 
position. (8) 
 
The modified VM with leg raise should have the greatest effect, due to the 
increased the venous return post VM strain, therefore causing an exaggerated 
overshoot in blood pressure in phase three. (8) In turn, this results in a more 
profound activation of the vagus nerve and a greater corresponding drop in heart 
rate. This theory is supported by studies showing that the standing VM is less 
effective at terminating SVT, only terminating 20% compared to 54%; this is 
thought to be due again to the higher sympathetic tone. (37) The modified VM 
was shown to be very effective compared to the semi-recumbent VM. (2,8) 
 
Variables which influence the VM 
The VM is a complicated process of neural and hemodynamic changes. A variety 
of factors affect the performance of the VM, other than have already been stated 
such as; volume and rate of the pre-strain breath, extent and rate of strain 
pressure increase, changes in lung volume and strain pressure, duration of the 
strain period, depth and rate of the post strain breathing.  (30) Conditions that 
influence venous blood return during the VM might also affect the manoeuvre’s 
efficacy. 
 
  
  
22 
  
Pre-strain breath 
This breath affects the VM as it determines the volume of the lungs and therefore 
the intrathoracic blood at the onset of the VM; this affects not only straining forces. 
(30) The changes in intrapulmonary blood have an enhanced effect on phase two 
of the VM, as they can cause a bradycardic response rather than a tachycardic 
response. (30) However, it has a minimal effect on phase four and one, making 
it less relevant to this dissertation, which is concerned with the bradycardic 
phases only as this is where most SVT terminations take place.  
 
Strain pressures  
This force of strain determines the intrathoracic pressure during the VM. It can be 
accurately measured, using a manometer, if the glottis is open while undertaking 
the strain. However, it is possible to produce the pressure using mouth pressure 
only (having a closed glottis) and therefore no intrathoracic transmission of 
pressure. This would not result in the classic VM phases and bradycardic 
response. (27) This is prevented by creating a small air leakage as pressure is 
quickly lost from the small volume of the mouth with such a leak but can be 
maintained with intrathoracic volumes. It is crucial, this leak is not excessive, as 
this would cause a drop in the intrathoracic pressure as the lungs vital capacity 
volume is lost. (27) Pressures of 30mmHg or lower have been shown to be 
ineffective at creating a VM. (22) The Ekinici study explored variation in pressures 
and found that there was no statistical significance between doing the VM at a 
pressure of 40 compared to 50mmHg. (38) If a pressure higher than 50 is used, 
there is a increased chance of syncope and other potential complications due to 
the drop in venous return being too large, reducing cardiac output and cerebral 
perfusion as demonstrated dramatically by Webber. (23,22) 
 
Duration of pressure 
The duration of 15 seconds has been used in previous studies that have 
demonstrated the effectiveness of the modified VM in SVT. (2) It reduces the intra 
strain tachycardia and replaces it with a steep rise in blood pressure ensuring a 
more significant and more prolonged post strain bradycardia. (18,8,27)  
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Few studies have compared the 15 second strain to other lengths; the Ekinci 
study compared a 10 second strain to the 15 second strain and found no 
difference. (38) This was followed by the Mehta study showing that the 15-second 
manoeuvre produced a greater vagal response compared to the 30-second 
manoeuvre. (37) Strains longer than 15 seconds have not been shown to have 
any advantage. They also have a larger theoretical risk of increasing side effects 
due to a prolonged drop in venous return reducing cardiac output, so shortest 
strain while maintaining efficacy should be used. (39,22)  With strains longer than 
15 seconds, it becomes harder for patients to hold the strain for the full length of 
time. A strain of greater than 20 seconds produces a more gradual reduction in 
heart rate compared to the more abrupt drop with the 15 second strain. (30)  
 
If there is a significant air leak in the VAD, patients may be unable to complete 
the 15 second strain preventing all phases of the VM being seen. (27) However, 
there is some evidence suggesting that a 10 second strain is all that is needed, 
so even if there is a leak, the strain will hopefully still be produced. (39)   
 
Baseline heart rate   
The baseline heart rate is highly variable between individuals and continuously 
under influences from internal and external stimuli. (27) It is essential to attempt 
to stabilise the heart rate before initiating the VM in experimental procedures 
whereas in spontaneous SVT this is not required. There should be enough time 
to allow participants to return to their resting heart rate. (27)  
 
Stimulants and Obesity 
Evidence shows that a participant’s response to the VM is reduced if they have 
consumed energy drinks in the last 60 minutes. (40) Energy drinks contain large 
quantities of caffeine which has been shown to affect the autonomic system. The 
caffeine causes an increased catecholamine release increasing the sympathetic 
innervation, therefore reducing the effect of a VM stimulating the vagal response. 
(40) Obesity was also shown to negatively correlate to the physiological drop in 
heart rate, though this effect is smaller than that of caffeinated drinks. (40)  
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Gender 
Gender was shown not to have an effect on the VM in terminating SVT. (37) 
However several studies show there are more women compared to men with 
SVT. (34,3) 
 
Age 
The Valsalva ratio is negatively correlated with age (p 0.06). (37) This is thought 
to be due to a decline in autonomic tone with increasing age, therefore meaning 
the VM is more successful in younger participants. (37)  
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Treatment of SVT 
The underlying principle in the treatment of SVT is to slow conduction through 
the AV node, through the action of the vagus nerve. Activation of the vagus nerve 
causes a pause long enough to interrupt the re-entrant electrical activity. (8)  This 
allows the underlying sinus node activity to become the only activity, and normal 
sinus rhythm is restored. (8) This is why NICE (The National Institute for Health 
and Care Excellence) recommends vagal manoeuvres as the first line treatment 
of SVT. (17) There are 3 main types of vagal manoeuvres including VM, carotid 
sinus massage and facial ice water immersion. It is discussed below why the VM 
is superior to these other vagal manoeuvres. The second line management is the 
use of a drug called Adenosine which is discussed below. 
 
For the management of SVT, it is important to assess the patient’s 
haemodynamic stability because if the arrhythmia is poorly tolerated it can cause 
hypotension (low blood pressure). If a vagal manoeuvre is performed on these 
patients, it can cause a further drop in cardiac output, resulting in worsening 
perfusion and syncope. For unstable patients, therefore, immediate chemical or 
electrical cardioversion is recommended. (7)  
 
Evidence behind the VM 
Examining previous evidence of patients whose SVT terminated, there were 
differences in which phase of the VM the termination occurred, this was 
associated with the type of SVT. (37) Of those who had AVRT antegrade 
terminations, 11% occurred in phase one and 89% in phase four. Whereas in 
retrograde termination of their SVT 94% occurred in phase two. (34) However, 
those with AVRNT retrograde termination, 100% occurred in phase two. This 
differs from antegrade termination where 86% terminated in phase four and 14% 
in phase two. (34) In AVRT the number of people with retrograde terminations 
was almost half of that of those with antegrade terminations, however, they are 
almost equal in AVRNT. (34) It is unknown, but this may be why VM is less 
effective in AVRNT compared to AVRT. We measured the bradycardic response 
because it is where the majority of SVT termination occurs.   
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Evidence has shown that the quicker VM is undertaken, the greater the likelihood 
of SVT termination. (8) This, not only reduces the need for antiarrhythmic 
medication (with greater side effects) but also prevents venepuncture and other 
potential complications from being in the hospital. (8) 
 
Evidence of other vagal manoeuvres compared to the VM 
VM vs Carotid Sinus Massage 
The most common vagal manoeuvres are the carotid sinus massage and the VM. 
(17) Previously it was thought these two manoeuvres had a similar rate of 
termination. (3) However, it has now been shown that the VM is much more 
effective than the carotid sinus massage, which is of very limited use. 
(41,42,43,44) Analysing various papers the rate of conversion was in the range 
of 5-54% for the VM compared to 0-17 % for the carotid sinus massage. 
(45,41,3,34)  
 
The literature on this topic indicates mixed results. A seminal paper by Lim 
showed that the VM and carotid massage have more similar rates of SVT 
termination (average success rate 18% and 11.8%) than otherwise shown in the 
literature. However, this could be due to the method of VM (40mmHg for 30 
seconds at a 90 degree angle) which has been shown to be less effective. (3) 
 
Taylor found a low rate of cardioversion with the VM at of 6.1%; this was superior 
to carotid sinus massage at 2%. (46) These results show a lower termination rate 
for VM than otherwise seen. This may be due to two things firstly the very small 
sample size of 18 people receiving VM and 13 receiving carotid sinus massage. 
Secondly, it is not stated how the VM was performed which greatly affects its 
efficacy. 
 
The most significant difference is shown in the Mehta study in which the VM 
converted 54% compared to 17% (p<0.001). This study was done on patients 
with a history of SVT who had it electrically induced for the trial. (37) This may 
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have made the patients easier to treat and so explain why it is more successful. 
However, the difference is marked and shows how much more effective the VM 
is. The ratio of the pre valsalva to post valsalva heart rates (valsalva ratio) was 
shown to be significantly higher in patients undergoing the VM compared to 
carotid massage (p=0.001). (37)  
 
The major downside of carotid sinus massage compared to VM is the greater 
number and severity of side effects including carotid atheroembolism, ventricular 
arrhythmias and stroke. (37) A recent article suggests that the neurological 
complication rate may be as high as 1%. (43) The efficacy of carotid sinus 
massage is dependent on pressure and correct direction of the pressure on the 
carotid sinus (operator skill). (3,47) The major risk of side effects and reduced 
effectiveness compared to the VM is the main reason the use of VM is supported 
in preference to the carotid sinus massage, as a first line treatment for SVT. (43) 
 
VM vs Facial Ice Water Immersion/Human Dive Reflex 
Facial Ice Water Immersion and Human Dive Reflex both result in cold-induced 
bradycardias. However they are the least common vagal manoeuvre used in 
adults. The human dive reflex (HDR) is thought to be similar to that of seals used 
to slow their metabolic and heart rates to enable long dives. (18) This treatment 
is popular in babies and infants with SVT, however, in adults it has been shown 
to be not very effective. The Mehta study showed that face immersion was worse 
than carotid sinus massage with a termination rate of 17% compared to 23%. (37) 
Smith and Broek also showed that the VM was significantly better than the HDR 
p<0.001.  (18) 
 
Pharmacological Treatments 
If vagal manoeuvres are unsuccessful, the ACC/AHA/ESC guidelines 
recommend adenosine as first-line medication. (7,1) This is due to its short half-
life, quick action and effectiveness. It has been shown to terminate SVT in up to 
91% of patients. (7) Adenosine works in similar ways to the VM by causing an 
atrioventricular nodal block; which blocks the refractive pathway and therefore 
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inhibits the re-entrant circuits. (48,49) Though adenosine is very effective it has 
unpleasant side effects for patients including dyspnoea, flushing, chest pain and 
most notably transient episodes of bradycardia. The latter can cause intense 
anxiety with many patients reporting the treatment is very unpleasant (sense of 
impending doom, or that they are about to die). (49,2,48)  Like other anti-
arrhythmic drugs adverse events can occur and include arrhythmias, most 
commonly premature ventricular or atrial complexes but it can also trigger non-
sustained ventricular tachycardia, atrial fibrillation. (10) Alongside this its 
bradycardic effect can cause more serious bradyarrhythmias especially in 
patients with sinus node dysfunction. (49) Due to possible bronchospasm 
Adenosine is contraindicated in patients with unstable asthma. In contrast, the 
VM is well tolerated, felt to be very safe and so it is so important to optimise the 
efficiency of the VM to reduce the use of adenosine or other pharmacological 
interventions. (50) 
 
If the first dose of 6mg adenosine does not terminate the arrhythmia, another 
12mg of adenosine is given, if still no cardioversion another 12 mg is given. (51) 
  
Other pharmacological interventions are administered if adenosine fails but are 
not in common use. These include verapamil, metoprolol, amiodarone or 
lidocaine. (52) 
 
Long-term Management for SVT 
Patients who have suffered an SVT frequently experience recurrences. For these 
patients, there are interventions that can reduce the frequency of attacks. 
Lifestyle changes, including reductions in the consumption of caffeine, alcohol, 
and cigarettes, as well as good levels of rest, have all been shown to reduce the 
frequency of SVT episodes. Medical management, including through beta-
blockers, verapamil, and digoxin, can also be considered. Finally, catheter 
ablation has been shown to cure 95% of recurrent SVT’s, though this is not 
without risk and is therefore used only following unsuccessful management with 
conservative and medical approaches. 
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Often the patient will have recurrent SVT, in these cases, specific interventions 
can help. The first intervention is lifestyle changes, cutting down caffeine, alcohol, 
cigarettes and ensuring the patient get enough rest. If this does not improve the 
patient’s symptoms, the patient is given rate control medications, e.g. beta-
blockers, verapamil and digoxin. If medication does not improve symptoms or is 
not tolerated, catheter ablation is used and cures 95% of SVT. However, it does 
have significant risks which is why it is the third line treatment, although in some 
practices it is used much earlier due to its more definitive actions. (53,54)  
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Chapter Two - Literature Review of the Valsalva 
Manoeuvre’s Effectiveness  
Introduction  
This chapter evaluates the efficacy of the VM using all levels of evidence. This 
review has two sections: section one examined the effectiveness of VM and its 
modifications, and section two examined the effectiveness of current strain 
creation. We are assessing whether the VM is a viable and effective first line 
treatment and whether it is possible there are improvements that could make it 
more effective. 
 
Method for Literature Review  
I initially explored the latest management of SVT using the BMJ and other clinical 
review articles for background information. I then searched for papers from 
August 2017 to May 2018, regarding the Valsalva manoeuvre using the TRIP, 
PubMed, ResearchGate, and Google Scholar databases.  I used the Zetoc Alert 
system to inform me of any new studies. A Boolean search was completed using 
the following search terms: Valsalva, SVT, supraventricular tachycardia, syringe. 
I also searched ClinicalTrials.gov for any ongoing studies. 
 
All papers that discussed the VM, its physiology, effect, creation or use were 
identified and screened. The references of recent studies were also searched for 
studies that may have been previously overlooked.   
 
Inclusion criteria for section one required the use of the VM on either healthy 
volunteers or on patients experiencing SVT. The inclusion criteria for section two 
required the assessment of strain production for a VM and assessment of the 
ability of health professionals to produce a VM. Both sections were restricted to 
those written in English and papers published from January 1985 to May 2018. 
Papers describing other uses of VM not relevant to our study were excluded.  
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Section One Identification of Papers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching (n=91) 
Records excluded (n=68) Records screened (n=102) 
Full-text articles assessed 
for eligibility (n=34) 
Full-text articles excluded 
(n=16) 
Studies included (n=18) 
Additional records identified 
through other sources (n = 11) 
Systematic 
Review (n=5) 
RCT 
(n=5)  
Repeated 
Measures 
Trial (n=2) 
Case 
Report 
(n=2) 
Figure 4 Method for Section One Literature Review 
Retrospective 
Study (n=3) 
Clinical 
Trial (n=1) 
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Section Two Identification of Papers 
 
 
  
Clinical 
Trial 
(n=1) 
Records identified through 
database searching (n=91) 
Records excluded (n=63) Records screened (n=102) 
Full-text articles assessed 
for eligibility (n=39) 
Full-text articles excluded 
(n=17) 
Studies included (n=22) 
Additional records identified 
through other sources (n = 11) 
Systematic 
Review 
(n=2) 
Figure 5 Method for Section Two Literature Review 
RCT 
(n=9) 
Repeated 
Measures 
Trial (n=2) 
Observational 
Study (n=4) 
Retrospective 
Study (n=1) 
Review 
(n=3) 
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Section One – Is the VM effective in terminating SVT? 
 
Efficacy of the VM  
The studies identified are shown in tables 1 and 2. The search identified three 
types of evidence: 
 
1. Clinical trials in patients presenting with acute episodes of SVT 
2. Trials conducted in the electrophysiology laboratory with induced SVT 
3. Systematic reviews 
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Clinical trials in patients presenting with acute attacks of SVT 
Four randomised controlled trials (RCTs), three retrospective/observational 
studies and two case reports were identified that examined patients in 
spontaneous SVT. This section discusses the outcome of this analysis.  
 
There have been a number of RCTs to assess the cardioversion rate of the VM. 
These trials have examined a variety of different modifications with varying 
success, discussed in theme two. In this section, these modifications will be 
ignored as they are discussed below. The largest RCT (REVERT) conducted on 
this topic found the standard VM had a conversion rate of 17%. (2) This was 
echoed by Lim (18%), Montemedi (14.8%) and Corbacioglu (10.7%).  (55,56,3) 
 
As a whole this evidence produced similar rates of cardioversion for the standard 
VM. It is the most reliable data as it was collected from patients with SVT. This 
indicates that the VM is an effective first line treatment for terminating SVT.  
 
There were some limitation to these studies. Corbacioglu used a syringe to create 
the VM which is not the gold standard, and has been shown to create variable 
pressures. (5) Lim study was different to other studies as it only allowed one 
attempt at each vagal manoeuvre before moving to the next. Further, patients 
were requested to hold the VM for 30 seconds, which has the potential to reduce 
the effectiveness of VM due to dropping the intrathoracic pressure as they hold 
it.  .  
 
The three retrospective studies present findings with a larger variation of potential 
termination rates, and suggest that VM is more effective when performed by 
specifically trained clinicians than when performed by those who are less skilled. 
In Walker’s study, the cardioversion rate rose from 5.3% (retrospectively) to 
31.7% (prospectively) when the clinician was trained to deliver a Trendelenberg 
VM. (35) This study used relatively small number of patients (n=19 for the 
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retrospective arm, n=27 in the prospective arm), which reduces the validity of the 
results. (35) Further, the fact that this study was performed in only one site limits 
the generalisability of the findings. 
 
Other studies show that if medical professionals understand how to produce a 
VM the cardioversion rate increases. Taylor recorded a termination rate of 16.7% 
which was similar to previous clinical trials but with only 37% patients presenting 
with SVT treated with a VM.  This could account for the study’s high rate of 
termination and reinforces the idea that more people need to understand how to 
produce a VM to make it effective at terminating SVT. (46) This is substantiated 
by Smith who assessed 212 patients showing a VM termination rate of 27.7%, 
with an unspecified VM and no teaching prior to the study. (57) This is a higher 
rate of cardioversion than seen previously in untaught participants and closer to 
REVERT’s termination rate. This may be due to the Australian paramedics 
receiving more education on the VM or similar to Taylor, only those who were 
confident in completing a VM carried one out. This is inferred as a further 409 
patients were still in SVT on arrival, most of whom had not been treated, but some 
may have received VMs that had failed so were not recorded, so it is hard to draw 
any conclusions. (57)  
 
It is difficult to interpret these retrospective studies as patients’ records document 
that a VM was completed, but do not always give the specifications of how it was 
produced. It is therefore hard to know if an appropriate VM was completed (30-
50mmHg for 15-30 seconds) and it is likely that some of these VMs were not true 
VM strains.  (60)  
 
Despite the limitations to the studies listed above, the body of available 
evidence seems to indicate that VM is an effective first line treatment in the 
treatment of SVT.  
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Trials conducted in an electrophysiology lab with induced SVT 
Two RCTs were conducted with patients in whom SVT was induced in the 
electrophysiology lab.  There is potential that induced SVT (by programmed 
electrical stimulation) may be more susceptible to reversion by vagal manoeuvres 
than a patient with spontaneous SVT triggered or maintained within the 
myocardium. (61) However, these studies allow for greater control of variables 
such as: anti-arrhythmic drug levels and potential causes of onset of the SVT and 
duration of attack that may affect the cardioversion rate.    
  
The Mehta study recorded a termination rate of 54% using a VM. This study 
shows the highest rate of termination by VM in the literature, possibly due to the 
greater susceptibility of cardioversion by induced SVT. (61) The VM in the study 
was a strain of 35mmHg for 15 seconds. Though other papers suggest 35mmHg 
is low for a VM, this study has shown this pressure is still effective in carrying out 
a VM strain. This VM also produced a greater drop in heart rate compared to the 
carotid sinus massage, indicating that this is key in termination of SVT. (37)  
 
Wen’s study was also carried out on participants with induced SVT but with a 
much larger number of participants (133 participants) than Mehta (35 
participants) giving their results more weight. (34,37) The VM performed in this 
study is different from the standard, as it was a 20 second strain held at a 
pressure of 35mmHg. This is similar to Mehta, suggesting that a pressure of 
35mmHg can produce an effective strain. The Wen results showed the VM 
terminated SVT in 53% with AVRT compared to 33% with AVRNT. (34) The 
average rate of cardioversion was 43%, slightly less than the Mehta rate of 54%.  
Thus the evidence is increasing in support of induced SVT having a termination 
rate of 43-53% using VM (at 35mmHg). (37,2,34) Wen’s study shows how 
effective a VM can be in terminating SVT. Their results are substantiated by the 
REVERT trial, showing that this may be possible in spontaneous SVT.  
 
The Wen study is interesting because it looks at potential explanations for the VM 
not terminating SVT, including patients having a lower vagal response in the 
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physiological testing causing a smaller reduction in RR intervals post VM than 
those that cardioverted. It was also shown that patients with AVRT had a greater 
vagal response during sinus rhythm, but we are unable to prove a causal 
relationship between AVRT and its higher termination rate. (34) The VM induced 
the most significant (p<0.05) vagal response in sinus rhythm and PSVT 
(paroxysmal supraventricular tachycardia) compared to other vagal manoeuvres 
(CSM, cold water to face). (34) 
 
Both the Wen and Mehta studies were carried out on people who have previously 
had SVT and many who had previously undergone VMs. This may have 
increased their chance of cardioversion as they were familiar with the manoeuvre 
and therefore had a greater chance doing it correctly. These results complement 
previous evidence showing that the VM is an effective first line treatment for SVT. 
However, it also reveals a significant degree of variation between results, 
indicating that there is the potential to improve outcomes.  
 
Systematic Reviews 
There are lots of small literature reviews, all calling for more research. The 
Cochrane Review in 2015 was unable to find substantial evidence to support or 
refute the use of VM in SVT. (61) However, this review only looked at 3 small 
RCTs with 316 participants, highlighting the need for more research and hence 
the inability to recommend the VM. The Smith Review in 2015 was more positive 
suggesting current evidence supports the use of VM in SVT, but called for 
additional research to standardise the manoeuvre and gain a strong evidence 
base. (22)  
 
A prehospital review showed there was no literature looking at using the VM out 
of hospital, partly due to the difficulty of carrying out a VM reliably in the 
prehospital environment. A retrospective study has since been carried out by 
the review’s author, Gavin Smith. (44) It would be a major advantage for most 
patients to be able to terminate SVT at home and avoid a hospital visit. (3) VMs 
need to be used more prehospital as there is evidence to suggest the earlier a 
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VM is completed, the greater chance of success; this will require an evidenced 
based review in due course. (6) To facilitate this advancement in the prehospital 
environment, the VM requires adaptation to improve ease of use.  
Efficacy of different modifications 
This section analyses the efficacy of modifications to the VM, to assess whether 
alterations to the VM can improve SVT termination rates. One systematic review, 
four RCTs, two repeated measures trials, two retrospective/observational studies 
and two case reports were analysed. The extra studies identified are on healthy 
volunteers and are shown in table 5 with their critical appraisal and a quick 
overview of the study. 
 
This section is divided into two sections 
1. Modified VM 
2. Previous Modifications 
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Modified VM 
In this dissertation we have defined a “modified VM” as undertaking a VM strain 
in the semi recumbent position but immediately at the end of the strain, patients 
are laid flat and have their legs raised to 45° for 15 seconds. (2) This is a relatively 
new concept first described by Appelboam in 2014, when the modified VM 
succeeded where other VMs had failed to terminate SVT. (59)  
 
The case report was followed by an RCT (REVERT) (n=433) which determined 
the effectiveness of the modified VM at terminating SVT. This research showed 
that the modified VM had a termination rate of 43% compared to 17% (95% CI 
2.3-5.8; p<0.0001) in the semi-recumbent position. (2) This is a large 
improvement that will improve patient treatment, but it has other benefits of being 
a low-cost intervention and having no increased side effect profile. (2) This 
modified VM has recently been substantiated by Corbacioglu and colleagues 
achieving a very similar cardioversion rate of 42.9% for the modified VM 
compared to the standard of 10.7 % (CI 6.8-53 p=0.007). (55) The Wheeler 
Review was produced after the REVERT trial and showed that the modified VM 
had a greater effect than semi recumbent position in SVT; though the fact that it 
relied heavily on the REVERT findings for its review reduces its contribution to 
our knowledge on this topic. (62) The REVERT trial itself provides robust 
evidence for the effectiveness of the modified VM, given its high patient number, 
strict protocol, and highly significant findings. 
 
These studies appear to show that the modified VM, as described previously, is 
significantly more likely to terminate SVT than the standard version. This has 
implications for patient care, as a more patients could be successfully treated in 
this way and thus avoid pharmaceutical management and the adverse events this 
is associated with. 
 
Previous modifications 
Previously various postural modifications have been studied, which include semi-
recumbent, upright, standing, Trendelenburg (head down position) and epigastric 
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pressure (abdominal pressure in supine position). These are discussed below. 
REVERT also showed that the more upright you sit, the less effective your VM 
will be in terminating SVT, as a semi-recumbent position produced a termination 
rate of 17% whereas a sitting upright showed a termination of only 10.7% . 
(55,2,3) A similar termination rate is shown by Lim of 18%. (3) However the 
position of the VM is not specified, yet from the picture they provide we can guess 
it was in the semi recumbent position which agrees with other evidence. 
 
No study has compared the modified VM to the gold standard supine manoeuvre. 
In Montamedi’s recent study, he showed that the supine manoeuvre was only 
effective in 14.8% of patients which is lower than the semi recumbent controls of 
the REVERT trial. (56,2) However Mehta showed that the supine manoeuvre was 
superior to the standing VM in terminating SVT in 54% compared to 20%. (37) 
 
The Trendelenberg manoeuvre was shown to be effective in terminating SVT in 
a case study which was then followed by two different studies. The initial study 
done by Walker and Cuttings showed that the Trendelenburg manoeuvre 
terminated SVT in 31.7%. The rate of successful cardioversion post-teaching and 
implementation of the Trendelenburg VM increased cardioversion rates from 
5.3% to 31.7%. (35) There was no standardised method of producing a VM prior 
to implementation of the Trendelenburg VM, meaning that though a VM was 
recorded, a VM might not  have been achieved due to incorrect procedure; this 
might account for differences in cardioversion rates compared to the REVERT 
control group (17% compared to 5.3%). (35,59) It is unknown whether the 
improvement post-teaching is due to the education or due to the Trendelenburg 
position as extant literature reports emergency physicians perform very poor 
VMs. (35,60) This is an inadequate study and it is impossible to draw any 
conclusions due to its flawed methodology and confounding factors stated above. 
The second study completed in 2014 on healthy volunteers showed the 
bradycardic effect of the Trendelenburg manoeuvre was not shown to be 
significantly different to the supine VM, which is easier to produce. (18) This 
shows that the Trendelenburg VM is unlikely to be superior to the supine VM. 
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Studies done on healthy volunteers showed there was no significant change of 
drop in heart rate between the supine VM and the Trendelenburg (p>0.9), which 
supports the finding that there is no advantage provided by the Trendelenburg 
manoeuvre. (18) Wong looked at a variety of modifications on healthy volunteers 
and showed that the supine technique was superior to the semi recumbent, sitting 
position and leg raise techniques. The reduction in heart rate was measured, and 
a difference of 2bpm between the supine technique and the semi recumbent and 
leg raise techniques was found. The sitting position produces a smaller drop in 
heart rate compared to the supine position with a difference of 3 bpm, however 
this was not significant. (8). The use of epigastric pressure during a supine VM 
has been shown to give no significant benefit compared to the supine VM. (8) 
 
Overall the evidence suggests that these modifications do not provide a 
significant benefit in the termination of SVT compared to the standard VM. 
 
Discussion 
This literature review demonstrates the utility of the VM in SVT and also the 
improved effects of a modified VM in clinical practice. It was difficult to compare 
the RCTs against each other as different methods were used. The most important 
difference was between the use of healthy volunteers with induced SVT and 
those with spontaneous SVT. Spontaneous (i.e. non-induced) SVT may 
represent a more accurate way to assess the utility of the VM, as induced SVT’s 
have a greater chance of resolution, both with and without intervention. (61)  (37) 
The fact that some studies use induced SVT participants and others use 
spontaneous SVT participants makes a direct comparisons difficult. 
 
Although the healthy volunteer studies were very effective and well carried out, 
their use is limited. Though a drop in heart rate has been shown to increase the 
likelihood of terminating SVT, this has not yet been proven to be a causal effect. 
(34) There are other potential causes of the VM not being as effective at 
terminating SVT, for example hemodynamic and electrophysiological 
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disturbances, which may affect the VM. However, as long as the autonomic 
system is intact and functional, the VM should have reproducible effects within 
SVT. (8,63) There is evidence linking the physiological effect of a drop in heart 
rate to a greater chance of SVT reversion. (34) This has also been shown by 
Mehta where the Valsalva ratio was shown to be significantly (p<0.001) higher in 
those participants who terminated their SVT than those that did not. (37) There 
are no studies examining the physiological effects of the modified VM. This study 
will therefore contribute to the evidence base for this treatment option. 
  
While no direct comparisons have been made between the supine VM (40mgHg, 
15s), which is the current gold standard, and the modified VM, the body of data 
available seems to suggest that the modified VM may be superior in terminating 
SVT. 
 
Conclusion 
Results from existing studies are hard to compare because of the differences in 
their methodology and especially differences within the technique of VM. This 
review shows that the VM is successful at terminating SVT and identifies the 
modified VM as the most effective method of VM. However, there is currently no 
evidence comparing the modification against the gold standard of supine VM. 
This study aims to address this issue.  
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Two – Effectiveness of strain creation  
Currently the VM is created using various methods, with the gold standard being 
the manometer. (2,18) The second most widely used and recommended for 
paramedics is the use of syringes. (64). However there is mixed evidence as to 
which is the most effective way to produce the VM to increase the efficacy of the 
VM. We have divided the review into four sections to examine each method. The 
objective of this review is to ascertain whether a device that aids in the delivery 
of a successful VM, and that can be used in the pre-hospital environment, would 
be of value in improving outcomes for patients presenting with SVT. 
1. Manometer  
2. Syringes 
3. Other methods of producing a VM 
4. Medical professional ability to perform a VM 
 
Manometer 
Manometers have been used since the 1920s to reduce the risks of doing an VM 
against a closed glottis. (22) In previous studies blowing into a manometer with a 
specified air leak was used as the standard for creating and measuring the 
appropriate intrathoracic pressure. (18) This is because it’s easy to measure the 
intrathoracic pressure this way. The manometer has been used in many large 
trials including the REVERT trial where it showed a cardioversion rate of the semi 
recumbent VM of 17% which is higher than that of the Corbacioglu study which, 
using syringes, showed only 10.7% cardioversion of supine VM. Potentially this 
shows that the manometer performed better than the syringe. However this 
difference is not clear because the modified group in the REVERT trial had a 
conversion rate of 43.5% compared to 42.9% in the Corbacioglu study. (2,55) 
The majority of studies have used manometers to record the pressures reached 
in the thorax while measuring the performance of the VM. This is due to the 
stability of pressure the manometer provides to make the VM as effective as 
possible. (2,55,37,34,3,30,45,18) There are currently no studies anlysing the 
efficacy of the manometer technique compared with the syringe technique in 
terminating SVT. We can conclude from studies done on syringes that pressures 
exhibited by syringes are not as exact as the manometer. (20) Thus the use of a 
manometer is preferable to reduce side effects and improve chances of a 
successful cardioversion. (22,65) 
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The main limitation of the manometer is its size, being very bulky and not easy to 
set up in an emergency situation. Vagal manoeuvres are much more effective 
when performed before the adrenergic tone rises so often work better at home 
than in the emergency room, particularly because there is often a long time 
between the start of SVT until treatment in the emergency room. (6) Therefore 
either ambulance crew or patients themselves need to be able to perform the 
procedure. This is why a device that is easily accessible, accurate and reliable is 
needed. Manometers are also becoming less available as they are being 
replaced by electrical blood pressure machines. However the latest study 
(REVERT) used a manometer with no air leak, and it did not seem to affect the 
effectiveness of the VM, so this is what I will use as my gold standard. (2) 
 
Syringes 
Several trials have looked into the efficacy of using syringes to perform the VM. 
(66) These trials are hugely variable and recommend different syringe types and 
sizes, indicating that the methods involved are inaccurate or the syringes 
themselves are variable.  
 
The Smith and Boyle study suggests that only a 10ml syringe is useful as no other 
size creates the correct pressure, but the limitations of this study are manifold. 
(67) Firstly, only ten syringes in each size group are tested, secondly it is unclear 
what pressure has been recorded – the lowest initial pressure or the lowest 
pressure needed to move the syringe in the next 15 seconds. This means that 
the pressures could be hugely variable. (67,5) 
 
The Thornton study had a different method, whereas in the Smith trial they had a 
patient blow and recorded the movement of the syringe, this study used a slow 
incremental increase in pressure by a manometer and recorded when the syringe 
moved, the plunger was then moved manually to 4 different positions each time 
checking the pressure required to move the plunger in its new position. (67)This 
will give a more accurate idea of what pressure is required, but it is not very 
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representative of the how a breath works although it is more accurate than the 
Smith paper. (67,5) Thornton study assessed 20 syringes in each size to assess 
the effect. Although this is an improvement on the Smith study it is still a very 
small number. This study showed that syringes are not an accurate way to 
reproduce the VM and could potentially produce serious side effects as 20% of 
syringes required greater pressures than the 40mmHg to move the plunger. (5) 
The range of pressures was approximately 30-160mmHg; creating pressures this 
high can have very severe consequences. There were no side effects recorded 
as this study was done using a manometer not a patient. These results are limited 
as only one brand of syringe was assessed and not by a randomised controlled 
trial on patients in SVT. Their poor performance can be applied across syringes 
which are not manufactured or designed for this purpose and thus lack quality 
assurance on achieving the right pressures, there is potential for other brands of 
syringe to create higher pressures. (5)  
 
Syringes have other limitations as well; a constant air leak is required to prevent 
supraglottic pressure requiring constant movement of the plunger during VM. 
However, this is problematic due to syringe size and the variation of gliding force 
along the syringe. (66) These trials demonstrated that all syringes had very high 
pressures if the plunger had not been previously moved. (5) The pressures also 
vary with movement of the plunger due to static friction which increases with time. 
This means if the plunger is moved to reduce the initial high pressure, we are 
unable to ensure the friction will be the same throughout the syringe, which in 
turns means that the required maintenance pressure of 40mmHg cannot be 
reliably achieved. (66)  
 
The current NICE guidance is to do a VM, and the example given on how to 
perform this manoeuvre is: blow into a syringe for 15 seconds lying down 
(supine). (17) This guidance may have been based on the evidence of Gavin 
Smith’s paper in which he did a very small unblinded study that showed that 8 of 
the 10ml Terumo syringes examined created pressures of between 30 and 50. 
(67) The international standard is to create a pressure of 40mmHg to achieve the 
maximal vagal response and that a pressure above 50 mmHg is the dangerous 
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limit. The Smith and Boyle study conforms to this. (67) However, as this would 
have to be recreated on a much larger scale to be a significant result, there needs 
to be a randomised controlled trial assessing the VM efficacy with the syringe 
against the manometer.   
 
Other ways of producing a VM 
There are several other ways of producing a VM; blowing against a closed glottis, 
straining like a defecation and creating an abdominal pressure. (65) Though not 
all of these create a true VM they are often used in practice due to the lack of 
available equipment to do a formal VM. These methods have not been tested, 
according to the literature, but as studies show that specific pressures are 
required to produce an effective VM. (30) We can say that these methods are 
almost useless due to the very variable pressures they create.  
 
Medical professionals’ ability to produce a VM 
Research findings show that doctors’ knowledge of the VM is poor and this is 
hindering patients’ treatment as VM is either being performed incorrectly or 
bypassed. (46)  As shown in the Smith study where, of the 882 patients admitted 
with SVT, the VM was only undertaken in 212 patients, it is often neglected in 
favour of drugs. (57) Lim also discovered that 12.2% of VMs were performed 
inadequately. (3) There have been four further papers examining this.  
 
Taylor and Wong showed that 91.4% of registrars and emergency medicine 
physicians performed a VM in an incorrect position with the majority placing 
people in an upright position greatly reducing the chance of successful 
cardioversion. This study showed how poorly VM is currently understood and 
used in most emergency departments. (60) 
 
The Honarbakhsh study showed that only 1/28 patients terminated their SVT with 
a VM, which shows an abnormally low conversion rate of 3.6% for the VM which 
may be due to incorrect methods. (68) One possible explanation for this is the 
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lack of clarity surrounding the use of the term “vagal manoeuvre”. It was not made 
clear whether this referred specifically to the valsalva manoeuvre, or to other 
vagal manoeuvres such as carotid sinus massage. This may have resulted in the 
abnormally low reversion rate. As this was also not a stated endpoint of the trial 
it is hard to draw any conclusions from this data.  
 
Smith and Boyle’s study showed that only 1/46 (2.2%) paramedics carried out the 
correct method of VM, with 34.8% getting patients to blow as long as possible. A 
VM is then very unlikely to take place as the correct pressure within the chest 
would not be created due to reduced lung capacity. (65) This was a cross-
sectional study with face-to-face interviews with paramedics who were asked how 
to perform the VM on a patient with hemodynamically stable SVT, while being 
blinded to the research question. This study gives a useful insight into the beliefs 
of paramedics around their own practice, and by ensuing the participants were 
blinded to the research question, the validity of the study is increased. However, 
the use of self-reported VM techniques, as opposed to directly observed real-
world or simulated practice, draws into question the validity of the findings, and 
could overestimate the paramedics’ ability to deliver an effective VM. 
 
One of the most compelling pieces of evidence is the Walker and Cutting study 
showing that with education and a standardised manoeuvre the cardioversion 
rate increased from 5.3% to 31.7%. (35) There was inadequate detail in patient 
records of how the VM was performed so a questionnaire was completed by a 
cross-section of 32 medical staff. This showed only 20% placed patients in a 
supine position, with the mean strain duration being 10 seconds, 13% asking 
patients to blow for long as possible. It was also shown that no one used a 
manometer and 93% used a syringe without the size specified. This suggests 
that very few true VMs performed due to a lack of knowledge. Doctors tend to 
overlook the VM, for many reasons such as lack of standardisation of techniques, 
lack of appropriate equipment, fears of the risk of harm (a remnant from carotid 
sinus massage), previous failure and ease of using Adenosine.  (46,60,68,69) 
Other factors impacting the use of the VM include poor education and instruction, 
therefore a small and easy to use device will increase the use of VMs. (60) This 
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shows the benefit of having a standardised, recognised VM which is simple to 
administer, has the potential to increase the correct use of VMs.  
 
Conclusion 
The literature suggests that current methods of producing a VM strain are 
inadequate in the pre hospital environment. The manometer was shown to be 
easy to use and can accurately produce a VM in the emergency department; 
however, it was too bulky for the prehospital environment. The literature also 
implies the need for a simple standardised method for the VM to improve correct 
completion by medical professionals improving its efficacy and use.  
 
A new portable device with instructions for a standardised VM is very much 
needed to utilise the pre hospital environment because the earlier the intervention 
the better the clinical outcomes. (65,6) It would also improve the delivery of the 
VM in the emergency department. 
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Complications of VM  
In designing a study using healthy volunteers it is important to be aware of the 
potential harmful effects of the VM. Any adverse reactions are very rare, and the 
VM is commonly accepted as a very safe procedure. (20)  Complications of this 
manoeuvre are more likely to be seen if the VM is done with too high a pressure. 
(22) As this would exaggerate physiological effects, mostly due to reduced 
venous return causing significant increased hypotension, increase in venous 
pressure and changes in the cerebral blood flow. (70) The exaggerated 
cardiovascular reflexes have been associated with increased morbidity and even 
mortality. (28) It has been shown in previous studies that pressure of 40mmHg 
for 15 seconds is a safe manoeuvre to carry out and if it rises above 50 mmHg, 
there is a higher risk of retinal haemorrhage or stroke. (22,20,37)   
 
However some serious side effects can occur in patients, these include chest 
pain, syncope (greatly increased with aortic stenosis), arrhythmia or stroke. (71) 
These risks are generally very low but are increased in patients with coronary 
artery disease (CAD) or cerebrovascular disease. (20) In patients with CAD 
where myocardial blood supply is reduced, ischemia can be precipitated by 
reduced venous return causing hypotension which increases the myocardial 
oxygen demand caused by high blood pressure after the strain. (28) The VM can 
also trigger arrhythmias, e.g. non-sustained tachycardia, conduction block and 
atrial fibrillation. This is thought to be due to changes in vagal tone and cardiac 
repolarisation being altered by ventricular loading. (28) Very rarely more severe 
consequences are seen, for example, due to the reduction of the left ventricular 
stroke volume during the manoeuvre complicated by inefficient autonomic 
regulation, it may contribute to a cardiac arrest. (20) Other complications can 
occur in the eyes, brain and lungs.  
 
The ocular complications are caused by a rise in intraocular pressure, which can 
trigger a retinal, macular haemorrhage (previously called Valsalva retinopathy or 
maculopathy) or glaucoma. (20,72)  
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Significant decreases in cerebral perfusion have been demonstrated during the 
strain phase, making the feeling of dizziness and fainting the most common side 
effect. (28) It has been implicated that this drop in perfusion followed by the rapid 
increase in blood flow can cause cerebral aneurysm rupture, though this is very 
rare. (28) The lungs can be damaged due to reducing pulmonary venous flow; 
decreased mucosal blood flow and size of upper airways, the most important 
consequence is barotrauma which can cause alveolar rupture leading to 
pneumothorax, subcutaneous emphysema, pneumomediastinum. (71) However, 
this risk is greatly increased with the concomitant use of drugs, e.g. marijuana 
and cocaine. (28) 
 
The majority of these cases are recorded as case reports due to the rareness of 
these side effects, however in this study, it is imperative that we do not put people 
at risk, so, we are excluding all patients with any eye, heart or lung disease, blood 
pressure of less than 100mmHg, pregnancy or any regular medications 
(excluding the oral contraceptive). These side effects are very rare-in a study of 
20,000 people no one experienced any complications. (20) Other more common 
side effects occur, which are much less serious for example: headaches, 
dizziness, musculoskeletal pain, nausea or altered vision, the most common of 
which was light-headedness and occasional premature ventricular ectopic beats. 
In a study of 65, these side effects only occurred in a few patients. (8,20) In the 
REVERT trial out of 428 patients only 21 patients had minor adverse events. 
These adverse effects were slightly increased in the modified VM group 
compared to standard manoeuvre. (2)  
 
Studies suggest that pressures above 50mmHg are likely to result in side-effects 
such as retinal haemorrhage or glaucoma but the use of 40mmHg as a safe 
pressure is supported by good evidence. (22) 
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Chapter Three - Valsalva Assist Device 
To improve the VM results the device needs to be small, portable, accurate, safe 
and easy to use. It has been shown that previous methods of blowing into 
syringes are very unreliable and can be unsafe due to high pressures created. 
(66,28) 
 
The benefit of this device is its user friendly design with simple instructions for 
performing a correct VM. This will be instrumental in introducing a standardised, 
easily reproduced VM. Introduction of the VAD is also a teaching opportunity to 
improve the effectiveness of the manoeuvre in emergency and pre hospital 
environments. (62) 
 
VAD development 
The initial idea was to develop a new small portable device which would enable 
patients to carry out their own VM safely and efficiently. Although a manometer 
was an accurate and reliable way to provide VM strains in trials, it has a number 
of problems for routine use, the first being its size, preventing ambulances from 
carrying them. The second problem is the creation of a small seal around a tube 
to create the appropriate pressure, as observed in ED some people are incapable 
of achieving this. 
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Figure 6 Original Device 
 
Novel design solutions for such a device were considered, however the 
investment required to produce these, such as new injection moulding equipment 
would have made the supply of devices for study prohibitively expensive. So we 
tried an alternative route using the company Meditech who make parts for airlines 
and anaesthetic circuits. Meditech utilised parts that were already available to 
create the initial device (shown in figure 6). It worked by employing an ALP valve, 
similar to anaesthetic circuits, which pops open at 40mmHg. During pilot and 
preparation work for this study, we found a potential problem with the proposed 
VAD.  The air leak was too great for some participants to complete the VM as 
described by blowing for the full 15 seconds. Whilst not dangerous, this would 
reduce the efficacy of the manoeuvre and be likely to confound the results of the 
study. The air leak is very important as it creates the correct intrathoracic 
pressure by opening the glottis.  
.  
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Figure 8  Valve in VAD 
Initially, we tried to reduce this air leak by applying a cap, as shown in figure 9. 
However, this was unsuccessful.  
 
Figure 9  Second Iteration of VAD with Pressure Measuring Attachment 
 
We then had to design a new device with a smaller air leak. We worked with the 
manufacturer towards a solution whilst still using a device that is CE marked and 
fit for purpose. This led to a period of innovation which involved Mr Clowrey 
Figure 7 Original Device with Filter 
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(Meditech managing director), Mr Mcleod (innovation lead at RD&E) and I visiting 
the Meditech factory. We tried a variety of techniques to improve the device using 
the same valve system so when the valve was triggered either sounds or a visual 
stimuli would be produced while also reducing the air leak shown in figures 10-
14. Unfortunately, none of these created the correct pressure reliably, and all the 
sound producing ones were too hard to hold for the full 15 seconds. 
 
Figure 10  Designing Station and Calibration 
We also found why the initial device had passed its industrial screening but failed 
on people. We had been testing the devices using air pressure with a volume of 
35 litres per minute which is not feasible by a human who has a maximum lung 
capacity of 5 litres and a tidal volume of 500ml.  
 
 
Figure 11 Attempts at Making Device Make Sound at the Correct Pressure 
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Figure 12 Attempts at Making Device Make Sound at the Correct Pressure 
 
Figure 13 Attempts at Making Device Make Sound at the Correct Pressure 
 
Figure 14 Attempts at Making Device Make Sound at the Correct Pressure 
 
After trial and development, we found a sample manometer that we could use. 
This turned out to be the most effective way to achieve a constant pressure 
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accurately so we added this to our mouthpiece to create our VAD as shown in 
figure 15.  
 
This device has several benefits including an actual manometer (pressure 
gauge), so the patient can see how high the pressure is. This new VAD will 
improve the standardisation and quality of the strain and reduce the chance of 
blowing at too high a pressure. We believe this VAD to be superior in design and 
closer to achieving our goal, an easy to use alternative device to a manometer. 
We ensured we have the best VAD to test so the study delivers its objectives but 
is controlled and safe.  
 
 
Figure 15 The Final VAD 
This design has been given registered design status.  
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Rationale 
The rationale behind this study is the need to provide an easy and accurate way 
of reproducing the VM and making it as effective as possible in the prehospital 
and emergency settings. The aim is to reduce the need for many hospital 
admissions, and give patients greater control over their conditions by using the 
device themselves, allowing them to terminate their SVT without the need for 
admission. 
 
The primary outcome of this study is to assess the effectiveness of the Valsalva 
assist device in reducing the heart rate of healthy volunteers, as this is correlated 
to successful cardioversion in SVT. 
 
The modified technique has already been shown to be superior in terminating 
SVT compared with the standard technique. (2) This study will compare the 
modified VM with the supine VM, which has not been examined before as a 
secondary outcome.  
 
Hypothesis  
The VAD will have a greater efficacy than the manometer at creating a VM in 
the supine and modified VM positions. 
 
The modified VM will cause a greater drop in heart rate (increased vagal tone) 
compared to the supine VM with both the manometer and VAD. 
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Chapter Four – Methods  
The trial was approved by the University of Exeter ethics committee and 
registered with ClinicalTrials.gov (NCT03298880). We performed a randomised 
repeated measures trial in the Clinical Research Facility between November 1, 
2017, and February 5, 2018.  
 
Power of study  
Sample size calculations were based on a simple paired t-test and the creation 
of a superiority study. There was no obvious way to determine the “smallest 
clinically important difference”, but we have used 4 beats per minute as a 
reasonably small difference, below which is unlikely to be important clinically. (18) 
With these parameters, a sample size of at least 73 participants provides 80% 
power at the 5% level of significance. We increased this to 75 to allow for any 
missing data in results.  
 
Participant selection and recruitment 
This study recruited 75 healthy volunteers, employing convenience sampling to 
recruit participants. They were recruited using posters and social media posts 
placed in the University of Exeter Medical School and the Royal Devon and 
Exeter Hospital. The majority of participants were current students at the 
University of Exeter. Potential volunteers sent us an email stating their interest in 
participating. Participant information was given out at least 24 hours prior to 
volunteers participating, so they had enough time to read and understand the trial 
and what they would be undertaking. Written informed consent was obtained by 
me prior to participation in the trial.  
 
To get the approval of the University of Exeter Ethics Committee we had to make 
sure our VAD was appropriately CE marked. The study was also approved by the 
Royal Devon and Exeter Hospital, so we could use their facilities. Two 
subsequent ethical amendments were made, the first to change the VAD we were 
using and the second to improve recruitment by using social media. 
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The inclusion and exclusion criteria are shown below. Participants were screened 
using a questionnaire to ensure they were healthy prior to their participation 
(shown in appendix D). This was self-reported, and no follow up was done. This 
was done to ensure the safety of the participants and to keep participants as 
similar as possible. We excluded pregnant women as they had an increased risk 
of fainting due to the reduction in venous return already impaired by pregnancy.  
We also recorded some demographic and health-related data on participants to 
enable possible post hoc analysis such as sex, age, and smoking status.  
 
 
 
 
 
 
 
 
 
 
 
Table 5 Participant Recruitment 
 
 
 
 
 
 
 
Participants screened (n=80) 
Participants randomised 
(n=75) 
Participants unable to 
complete trial (n=0) 
Participants included in 
analysis (n=75) 
Participant’s excluded (n=5) 
 Cardiac murmurs: 2 
 Cardiac arrhythmias: 2 
 On medications: 1 
 
  
  
65 
  
Inclusion and exclusion criteria 
Inclusion Criteria 
Adult volunteers 18-60 year-olds 
Sinus rhythm on initial ECG 
Self-reported good health 
Exclusion criteria 
Any regular medication other than the oral contraceptive 
Previous cardiovascular or respiratory disease 
Any contraindication to performing a VM (e.g. known aortic stenosis, recent 
myocardial infarction, glaucoma, retinopathy) 
Pregnancy 
Any ECG abnormality 
Any contra-indication to postural modification (any reason the participant can’t lie flat 
and have both legs lifted to 45 degrees, e.g. prosthetic hip 
Inability or refusal to give written consent to take part. 
Observations of the pulse, oxygen saturations, respiratory rate or blood pressure 
outside the normal range. Specifically blood pressure less than 100 systolic 
Caffeinated drinks within 6 hours prior to testing 
The use of stimulant drugs or alcohol within 24 hours prior to testing 
 Table 6 Inclusion and Exclusion Criteria  
 
Our method was based on previous studies using healthy volunteers and trying 
to reduce bias as much as possible. (8,18) We used similar inclusion and 
exclusion criteria to previous studies and did our own literature review (chapter 
two) to rule out any possible risks to the safety of our participants. We excluded 
participants who had had caffeinated drinks within the last 6 hours as this would 
reduce their response to the VM. Though obesity would also reduce the response 
to the VM, it is a much smaller reduction, so we did not exclude these participants 
as this may have hindered our recruitment and ethics approval. As age affected 
the VM response, we have excluded participants older than 60 years. Participants 
taking recreational drugs have a much higher chance of adverse events, so were 
also excluded. 
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Research design  
After screening I conducted some general observations to check each 
participant’s health.  Their heart rate, respiratory rate, oxygen saturation and 
blood pressure were recorded prior to starting the manoeuvres using a vital signs 
monitor (Dinamap V100). Participants also underwent a respiratory and cardiac 
examination by me, to ensure that the basic examination was normal. A 12 lead 
ECG was then carried out (MAC 1200 ST) and reviewed by me. If all of the above 
were normal, then participants continued in the trial. 
Testing was conducted indoors with a mean ambient room temperature of 22 
degrees. Each participant underwent four VMs of the four variations shown 
below.  
1. Supine VM using manometer. Supine Valsalva strain using a 
manometer visible to the participant with a target of 40mmHg for 15 
seconds. 
2. Supine VM using VAD. Supine Valsalva strain using the VAD 
connected to manometer invisible to the participant but visible to a 
researcher for 15 seconds. 
3. Modified VM using manometer. Participant at 45 degrees, Valsalva 
strain using a manometer visible to the participant with a target of 
40mmHg for 15 seconds followed by supine positioning and passive 45 
degree leg lift immediately at the end of the strain for a further 15 
seconds (modified VM). 
4. Modified VM using VAD. Participant at 45 degrees Valsalva strain using 
the VAD connected to manometer invisible to the participant but visible to 
a researcher for 15 seconds followed by supine positioning and passive 
45 degree leg lift immediately at the end of the strain for a further 15 
seconds (modified VM). 
 
Each participant received spoken instructions on how the study would be carried 
out. These instructions are found in appendix D. Participants were allocated to 
their order of VMs and their participant number using pre-randomised sealed 
envelopes. The order of VM was previously randomised and stratified to create 
the same number of the different orders of VM. This was done by listing all the 
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possible orderings and then used a random number generator to determine the 
ordering. This was repeated three times and then the last few were completely 
randomised.  Each time a VM was carried out the randomisation form was signed 
by an independent researcher who was not a part of the research team. This was 
to remove the possibility of completing an order different to the one specified by 
the randomisation. Then the three-lead ECGs were attached and tested to ensure 
they were attached correctly. In this study, everything was explained to make the 
participant aware and to reduce anxiety. After correct positioning, participants 
were given five minutes of rest time to enable them to return to their baseline 
heart rate. The trace was started 15 seconds before the VM. 
The strains are intuitive with feedback from the manometer or VAD, and no 
practices were allowed. A laptop stopwatch was used to time strains and was 
visible to participants. Participants were instructed to stop blowing after the 15 
second strain, but no other encouragement or instruction was allowed. The ECG 
trace was stopped 15 seconds after the end of the VM. We chose 15 seconds for 
the strain as the available evidence suggests this is the best method and the 
majority of the evidence used 15 seconds, so we would have a similar risk of 
adverse effects. The 15 second strain also enables greater compliance to the 
manoeuvre than longer strains. (18,60) We tried to ensure that all participants 
completed the 15-second strain. However, we were concerned that significant air 
leaks in the Valsalva assist device might make this problematic and could affect 
the trial. 
 
 
No participant was allowed to blow more than 50mmHg on either the manometer 
or VAD, due to the increased risk of side effects being caused above 50mmHg. 
In the unlikely event of VAD malfunction (i.e. it provided no resistance or 
resistance was greater than 50mmHg), the VM would have been immediately 
abandoned, and the malfunction recorded as an adverse incident. The 
manoeuvre would then be restarted using a new VAD if the participant was happy 
to continue.  
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All testing was performed on a standard hospital trolley in the clinical research 
facility with a manually adjustable backrest. A 45-degree-angle template was 
used to ensure consistent leg elevation angle where needed.  A protractor was 
used to measure and create a back angle of 45 degrees for each modified VM.  
 
Each participant was asked to take enough breath to complete the manoeuvre 
before blowing into the VAD or manometer. This was done to try and remove the 
size of breath intake as a factor affecting the response of the VM. This was 
explained to each participant at the outset. We know it is crucial to have an air 
leak while performing a VM to ensure an open glottis and correct intrathoracic 
pressures. However in ED where the manometer is most commonly used there 
is no easy or standardised way to create a leak in the circuit. Therefore this is 
very rarely done. We replicated this in our study and did not add an air leak to our 
oxygen tubing. 
 
 
A new VAD and a new 92cm length of green oxygen bubble tubing for the 
manometer (Welch Allyn Maxi Stabil 3 A grade) was used for each participant. 
The tubing was 92cm to ensure the diameter of the tubing was the same and long 
enough to reach the participant, due to the bubble tubing changing diameter with 
length. The tubing was replaced with each participant for hygiene reasons but it 
was unnecessary to replace the manometer, since it has no appreciable flow of 
air across it. How quickly the participant was able to reach the appropriate 
pressure and fall at the end may be very important for the heart rate response. 
To rule this out as an effect, we ensured that participants achieved appropriate 
pressure levels as soon as possible (included in standard instructions). 
 
There was a three-minute washout period between strains including two minutes 
rest after any change in posture. A continuous three-lead ECG monitoring on a 
standard print (running at 25mm/second via defibrillator (Heartstream XL 
defibrillator) was used to assess heart rate during the manoeuvre. An ECG 
rhythm strip trace was printed for 45 seconds (15 seconds before, during and 15 
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seconds after each VM). Points were marked at the onset of each Valsalva strain, 
labelled with a code and subsequently analysed, blind to technique according to 
the method described by G Smith. (18) ECGs were marked with each 
participant’s number to enable the investigator to be blinded at a later date. 
 
Pre-manoeuvre heart rates were determined by calculating the mean R-R interval 
of the 10 beats preceding each manoeuvre before converting it to heart rate in 
beats per minute (bpm). The lowest post manoeuvre heat rate was determined 
by measuring and recording the longest R-R interval during, and up to 15 seconds 
post, manoeuvre. This was also converted to a heart rate in beats per minute. 
The difference between the pre- and post-manoeuvre heart rate was taken to 
indicate the degree of vagal tone or slowing of heart rate induced by each 
manoeuvre. This was calculated as the post VM value minus the pre VM value, 
in seconds. (18) Intervals, where a premature ectopic complex resulted in a 
compensatory pause, were excluded from the pre-manoeuvre R-R interval 
measurement. Non-differential measurement bias is likely to have affected the 
accuracy of results because R-R interval measurement directly from an ECG strip 
is inherently inaccurate. To minimize this inaccuracy, blinding of the investigator 
who undertook ECG measurements was instigated to minimize observer bias and 
then repeated by a different blinded investigator who was not a member of the 
research team. (8) The Valsalva ratio was calculated by dividing the pre 
manoeuvre heart rate by the post manoeuvre heart rate.  
 
Peak sustained pressures achieved as observed on the manometer and duration 
of longest strain attempt during all VMs were recorded on a standard report card 
to allow comparison of the different strain techniques. Participants were closely 
monitored for any adverse events. No major side effects were experienced; any 
participant that felt unwell or developed any significant or persistent ECG 
abnormalities, were immediately withdrawn from further testing, and appropriate 
further clinical assessment arranged. All adverse events were recorded, graded 
and reported immediately to the CI and University of Exeter and reviewed by the 
study team.  
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Statistical analysis 
The study aims were to measure the mean difference in RR interval and mean 
difference in heart rate values pre- and post-manoeuvre; these were calculated 
from each type of manoeuvre and compared. The mean difference between the 
different types of VM was also compared. The two end comparisons we assessed 
were: 
1. Supine VM vs modified VM (recognising that this comparison may or 
may not be different according to which instrument is used – manometer 
or VAD) 
2. Manometer vs VAD (recognising that this comparison may or may not be 
different according to the posture adopted – supine or modified) 
  
The analysis was based on mixed-effects linear regression (with an appropriate 
assessment of assumptions, e.g. normality), with the individual as a random 
effect, position (supine/modified) as a fixed effect, and instrument 
(manometer/VAD) as a fixed effect. An interaction term (position and/or 
instrument) was examined to consider whether there was any evidence of a 
differential effect (of the device according to the position, or equivalently position 
according to the device), but was dropped from the model if p>0.1.  The 
interaction term was dropped so the two comparisons were presented overall. 
The statistical analysis was undertaken using STATA and Excel software.  
 
Reducing bias 
A standardised set of instructions for the procedure was created and printed out 
(see in Appendix D). This was to ensure that all participants received the same 
instructions, to rule out any potential instructional bias.  
A mixed linear regression analysis was carried out, to assess whether or not the 
manometer or VAD affected the analysis of the supine vs modified VM and vice 
versa.  
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Data collection 
The screening data was kept with each participant file. The ECGs were kept with 
the VM data sheets for subsequent analysis and were stored securely in the 
Clinical Research Facility.  
 
Strain pressures analysis 
35mmHg to 45mmHg was chosen as the limits of an acceptable pressure as the 
lower limit has been shown to be just effective if not more effective than 40mmHg. 
(37) This made it reasonable to assume the same variance was acceptable in the 
upper limit. 
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Reflection on Challenges 
Our first challenge was receiving ethics approval, this took much longer than 
expected with many revisions and comments from the ethics committee. The 
initial ethics application was submitted in June yet it was not approved until the 
beginning of September. It was a very enlightening experience about how ethic 
committees work and how precise you have to be when writing an application. 
You have to think through every possible outcome of your study and how you 
would cope with serious adverse events. At the time this felt very forced and 
unrealistic. However I realised how important this is during my study and how 
essential it is that you have thought of how deal with these things before they 
happen. It was reassuring to know I had these plans in place. 
 
We trialled our study protocol, which was a very useful exercise because it 
exposed several methodological issues. The first being the complexities of roles 
and creating standard operating procedures that would work and flow. Secondly 
we discovered the VAD did not work as anticipated and had to improve it before 
we could start. Thirdly we identified how to mark and measure the ECGs.  
  
During the study itself we faced a variety of challenges, firstly the use of a variety 
of assistants. We tried to reduce the number, but every new assistant we used 
made the first modified VM jerky even if we practised beforehand. This may have 
had a consequence on participants as they may have reacted to falling 
backwards even though they were supported.  
 
The unfamiliarity of the VAD meant it was difficult to use as intended; often the 
second attempt was much better as the participant became familiar with the VAD. 
This often prevented participants from running out of breath the second time. 
Initially, participants found it difficult to read the VAD, but participants did much 
better after I demonstrated one.  
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Our main challenge was recruitment. Initially, I thought that this would be easy as 
we had a large cohort of medical students that would be keen to take part. 
However, it was much harder than I imagined to encourage people to participate. 
Our initial poster campaign was not as effective as hoped, so we applied for an 
ethics amendment to be able to advertise on social media and this proved much 
more effective.  
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Chapter Five - Results 
A total of 75 healthy participants, 30 male (40%) and 45 female (60%), were 
recruited to this study. The mean age of participants was 26 (range 19-55 years). 
Table 8 shows the baseline characteristics of participants. All participants 
completed the study, and there were no missing data. However, there was one 
VAD malfunction with the pressures reaching 55 and recording only 40mmHg on 
the VAD. Five participants failed screening and were excluded from participating, 
due to participants having heart murmurs (2), arrhythmias (2) or being on 
medication (1). Due to such low numbers of smokers and small spread of age, 
we were unable to do a post hoc analysis of these effects. 
  
  Participants 
Mean age  26.19 years 
Age range   19-55 years 
Base HR  76 bpm 
Base blood pressure  123 / 71mmHg 
Smoker  5 
Never smoked/former 
smoker 
 70 
Oral contraception   10 
Medication  2 
Past Medical History  3 
Table 7 Participants Characteristics  
 
 
Agreement of readers 
Two readers analysed the ECG strips. For the 10 beats prior to the manoeuvre, 
there was very good agreement: both reporting overall means of 180.8mm. 
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Both reported 71% of the 300 readings were identical, with 99% of readings 
within 1mm and the (single) worst discrepancy being 2.5mm. For the post VM, 
longest RR interval, the two readers recorded overall means of 27.8mm, with 
80% of readings identical and 100% within 1mm. A simple average of these two 
readings was subsequently used in the analyses.  
 
Modified VM compared to the supine VM  
The raw data collected from every WM undertaken is shown in figure 17. This 
figure shows the change in heart rate was larger in the modified VM compared to 
the supine VM. Due to the normal distribution of data it is easier to view as a 
mean value. The original data is found in appendix G. 
 
Figure 16 Comparing Raw Data: The Change of Heart Rate of the Modified VM vs Supine VM 
 
The results are shown in table 9. Both groups showed a significant drop in heart 
rate following the VM, with all having a Valsalva ratio >1.3. The modified VM had 
a greater drop in mean heart rate than the supine VM, with a difference of 7.6 
bpm.  
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Manoeuvre Mean pre 
manoeuvre heart 
rate (bpm) 
Mean post 
manoeuvre heart 
rate (bpm) 
Mean difference 
heart rate (bpm) 
Valsalva 
ratio 
Modified VM 88.3 54.6 33.7 1.66 
Supine VM 83.0 56.9 26.1 1.47 
Table 8 Modified VM Compared to Supine VM Raw Data 
 
However, the modified VMs pre heart rate started at a higher rate as shown in 
figure 18 and table 9. A mixed linear regression was completed to assess the 
statistical significance of these results.  
   
 
Figure 17 Change in Heart Rate of the Supine vs Modified Manoeuvre. 
 
The coefficient was calculated for the difference in drop in heart rate (bpm) at -
3.7 (95% CI 2.1 to 5.3; p<0.001). This is the statistically adjusted drop in heart 
rate. This was analysed for potential confounding factors (device or manometer 
and order of VM’s) and has been adjusted allowing for baseline heart rate due to 
a high resting heart rate. If we remove the high pre VM heart rate as an interaction 
the coefficient becomes 7.7 bpm (5.6 to 9.8 p<0.001). This analysis is shown in 
table 10. 
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Manoeuvre Significant 
reduction in mean 
difference (HR) 
Confidence 
intervals 
P value Standard 
error 
Modified vs supine 
mixed linear 
regression 
3.8 2.2 to -5.4 P<0.001 1.12 
Modified vs supine -
removed the higher 
pre VM heart rate 
7.6 5.5 to 9.7 P<0.001 1.08 
Table 9 Modified VM Compared to Supine VM – Mixed Linear Regression 
  
VAD compared to the manometer  
The results of the VAD compared to the manometer are shown in table 11. Each 
VM showed a significant drop in heart rate following the VM, all with a Valsalva 
ratio >1.3. The manometer showed the greatest drop in heart rate compared to 
the VAD.  
 
Table 10 Manometer and VAD Raw Data, Heart Rate 
Manoeuvre Mean pre 
manoeuvre heart 
rate (bpm) 
Mean post 
manoeuvre 
heart rate (bpm) 
Mean difference 
heart rate (bpm) 
Valsalva 
ratio 
Manometer  85.5 54.7 30.7 1.59 
VAD 85.8 56.7 29.0 1.53 
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Figure 18 Change in Heart Rate Raw Data With the Manometer vs VAD 
 
Figure 19 shows that the raw data appears to be very similar for the manometer 
and the VAD. Yet the comparison of the mean heart rate difference between the 
manometer and the VAD (shown in figure 20) shows a greater drop in the 
manometer group. The original data is found in appendix G. The difference in 
heart rate drop of the manometer compared to the VAD was 2.17 bpm. A mixed 
linear regression was completed to assess the statistical significance of these 
results, shown in table 12. 
 
Figure 19 Comparing the Pre and Post VM Heart Rate Analysing the Manometer vs the VAD 
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Manoeuvre Significant 
reduction in 
mean difference 
(HR) 
Confidence 
intervals 
P 
value 
Standard 
error 
Manometer vs VAD – 
mixed linear regression 
1.9 0.04 to 3.4 0.01 1.09 
 
Manometer vs VAD – 
removed the higher pre 
VM heart rate 
1.7 0.4 to 3.8 0.11 1.08 
Table 11 Statistical Analysis of the Manometer and VAD 
 
Statistical analysis shows the manometer produces a greater drop in heart rate 
compared to the VAD, with a coefficient of 1.9 bpm (95% CI 0.4 to 3.4; p=0.01). 
However if we remove the high pre VM heart rate as an interaction, the coefficient 
becomes -2.0 bpm (95% CL -4.1 to 0.1; p=0.06).  
 
There appears to be very little difference between the manometer and VAD, with 
most of the difference appearing in the supine group of the VAD group (this was 
shown to not be significant p>0.05).  
 
Valsalva ratio 
We assessed participants’ Valsalva ratio to determine the effect of the VMs and 
more easily compare ours to previous studies. Figure 22 shows the spread of 
data for the modified VM vs the supine VM. 
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Figure 20 Valsalva Ratio Raw Data of the Modified VM vs Supine VM 
 
From figure 22 it is evident that the modified VM has a greater Valsalva ratio than 
the supine VM in the majority of participants. Figure 23 shows the Valsalva ratio 
of the VAD and manometer.  
 
 
Figure 21 Valsalva Ratio Raw Data of the Manometer vs VAD 
 
Figure 23 shows that the majority of the VAD and manometer Valsalva ratios are 
very similar.  We assessed the mean of the Valsalva ratios to see if there was a 
true difference between the groups shown in figure 24.  
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Figure 22 Valsalva Ratio  
 
The modified VM has a much larger Valsalva ratio than any other group. Figure 
24 shows that the manometer and the VAD had a difference in means of 0.07. 
 
Statistical analysis 
For the type of VM and the device analysis, we used a mixed linear regression. 
First we ran a model including an interaction term for type of device and 
manoeuvre to allow for the possibility that any difference between devices varied 
between manoeuvres (and vice versa). There was no evidence of such an 
interaction (p=0.70), hence we removed that term and included only main effects.  
 
The next thing we examined was whether the order of VM had an effect when we 
inputted this data as a categorical variable and this was shown not to be 
significant (p=0.32). When inputted as a continuous variable (suggesting a linear 
change as we go from 1-4), it is just significant at p=0.049. However it makes 
very little difference to our estimates of the effect (or p values) of VM done and 
device used so we excluded this as a variable.   
 
1.35 1.4 1.45 1.5 1.55 1.6 1.65 1.7
modified VR
supine VR
VAD VR
Manometer VR
Valsalva ratio
Differences between mean Valsalva ratios
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The independent variables included for the mixed linear regression were; type of 
device, type of VM and “person” as a random variable. 
 
Supine VM was associated with a lower resting pre-VM heart rate, probably 
representing a higher degree of initial vagal tone in this starting position 
compared to the semi-recumbent position in the modified VM.  In that case, it may 
arguably be relevant to consider the absolute reduction in heart rate without 
adjusting for the baseline rate.  Re-running the model without the baseline, the 
modified VM was seen to have produced a greater reduction in heart rate than 
the supine VM by 7.7 bpm (5.6 to 9.8; p<0.001), while the comparison between 
devices no longer reached the traditional level of significance: the manometer 
reduced heart rate by 2.0 bpm more than the VAD (-0.1 to 4.1; p=0.06). 
  
Pressure and duration of VAD and manometer 
Table 13 shows the mean and range of pressures the VM reached and duration 
it was held in relation to the VAD and the manometer. However, due to the 
skewed data shown in figure 25 and 26, the mean is not a good representation 
of the pressure or duration achieved. 
 VAD Manometer 
Pressure mean (mmHg) 42.46 39.96 
Pressure range 30-50 25-50 
Duration (s)  13.70 14.91 (14.99 exclude 
outliner) 
Duration range 5-15 4-15  
Table 12 Averages of Duration and Pressure 
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Figure 23 Raw Data of Pressure of Strain Duration 
 
Figure 24 Raw Data of Pressures Achieved 
 
Duration 
We categorised the data according to duration, setting out whether 15 seconds 
was achieved or not. We examined whether the modified or supine positioning 
had any effect on duration, and it was shown to have no effect (data is shown in 
appendix E). Tables 14, 15 and 16 show the number of VMs that achieved a 
duration of 15 seconds = yes or <15 = no, with percentages shown below.  
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Supine VM:    Modified VM: 
  
 
 
 
 
 
 
 
                Table 14 Duration of Strain Achieved in the Modified Position 
 
Overall: 
 
 
 
 
 
 
 
 
Table 15 Duration of Strain Achieved by the VAD and Manometer 
 
People are less likely to achieve 15 seconds with the VAD than the manometer, 
independent of whether supine or modified VM. Overall the type of VM does not 
affect the ability to achieve 15 seconds, but the type of device does. Statistical 
analysis was undertaken using McNemar’s test. The VAD was significantly less 
likely to produce a time of 15s compared to the manometer in the supine and the 
modified VM (p<0.001 and p<0.001).  Examining the type of manoeuvre, the 
effect was not significant for either the supine VM or the modified VM (p=0.15, 
p=0.13). 
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New Device          63         87         150 
                                             
                  2.00      98.00      100.00 
 Manometer           3        147         150 
                                             
         e          No        Yes       Total
Type_Devic           (s))
             (Total time of breath
              Totaltimeofbreaths
                   RECODE of
VAD 
                 23.33      76.67      100.00 
     Total          35        115         150 
                                             
                 45.33      54.67      100.00 
New Device          34         41          75 
                                             
                  1.33      98.67      100.00 
 Manometer           1         74          75 
                                             
         e          No        Yes       Total
Type_Devic           (s))
             (Total time of breath
              Totaltimeofbreaths
                   RECODE of
VAD VAD 
 Table 13 Duration of Strain 
Achieved in the Supine 
Poistion 
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Pressure 
We analysed the pressures created, we grouped the data into two groups; 
achieving pressures of 35-45, or not achieving these pressures. We then 
compared the type of manoeuvre and the type of device used to see if either had 
an effect. We used a McNemar’s test for assessing the statistical importance of 
the different pressures achieved. Table 17 and 18 show the number and 
percentage of VMs that are in the two groups.  
 
VAD               Manometer 
 
Table 16 Pressures Achieved by the VAD                 Table 17  Pressures Achieved by the Manometer  
 
The mean strain pressures delivered by manometer and VAD were similar (39.96 
vs 42.46 mmHg). Regardless of the position of the VM (supine or modified), the 
manometer was more precise, with 97% of participants straining between 35-
45mmHg compared to 75% when using the VAD. 
 
On statistical analysis, it was shown that the type of manoeuvre did not affect the 
pressure (when using the manometer, p=0.72, when using device p=1.0). 
However, it was shown that the type of device did affect the pressure, with more 
people achieving the desired pressure with the manometer than the device 
(p<0.001 for both supine and modified VMs). 
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So, whether for supine or modified VM, people are more likely to produce 
>40mmHg with the VAD compared with the manometer. Examining the VAD in 
more detail, 30 people achieved 40mmHg when supine, compared to only 18 in 
the modified VM. With the modified VM there was an increased number of 
pressures over 45mmHg, as shown in table 19. 
 
 
 
 
 
 
 
Adverse events 
22.7% of participants experienced adverse events, which was much higher than 
in previous studies. All of these adverse events were transient. No serious 
adverse events were exhibited. The number and type of adverse events are 
shown in table 20. The most common side effect was a headache and light-
headedness.  Some participants exhibited more than one side effect. 
 
 
Table 18 Pressure Created by the VAD in Supine and Modifed Positions 
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 The Modified VM The Supine VM 
 VAD Manometer VAD Manometer 
Lightheaded 3 2 1 1 
Tingling lips 1 0 0 1 
Ectopic 1 0 0 0 
Rib strain 1 0 0 0 
Head rush 0 0 0 1 
Unable to blow 
into tube 
0 0 0 1 
Headache 1 6 4 6 
Vision changes 0 0 0 2 
Chest discomfort 1 0 0 0 
Device failure 0 0 1 0 
Totals 8/75 8/75 6/75 12/75 
Totals Modified 
and Supine 
16/150 18/150 
 
Table 19 Side Effects of the Supine VM Compared to the Modified VM with Subgroups of VAD and 
Manometer. 
 
The number of participants that exhibited adverse events is shown in table 21. 
Examining the raw data, it appears that the VAD exhibited less adverse events. 
We conducted a mixed-effects logistic regression with a binary outcome of “any 
side effect”. There was no statistical evidence determining whether the VM type 
or device type affected the risk of adverse events (p=0.80 type of VM, p=0.08 
type of device).  
 
Number of participants experiencing side effects 
Type of manoeuvre Modified VM Supine VM 
VAD 8/75 6/75 
Manometer  8/75 12/75 
Table 20 No. of Participants Experiencing Side Effects 
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Chapter Six – Discussion and Conclusion 
Discussion   
Our results show that the modified VM is statistically superior to the supine VM 
at producing a reduction in heart rate, indicating the physiological advantage of 
the modifed VM. This was shown by the higher vagal response exhibited by the 
modified VM with a larger absolute and relative drop in heart rate compared to 
the supine VM. This is consistent with the increased effiicacy seen in previous 
clinical trials (2,55). 
 
The modified VM is associated with a higher pre VM heart rate (probably due to 
an initial decrease in vagal tone in this position to maintain cerebral perfusion). 
The exaggerated changes to venous return resulting from the semi-recumbent 
position in the strain phase and leg elevation in the supine relaxation phase 
(Valsalva phase three) result in more intense vagal stimulation overall with the 
modified VM. This causes a greater drop in heart rate and a larger Valsalva ratio. 
Previous studies show that a larger Valsalva ratio correlates with a greater 
chance of SVT being terminated by the VM. (37)  
 
This higher baseline heart rate in the modified VM significantly affects our 
statistical analysis, causing the initial adjusted mean drop in heart rate to be lower 
than expected. If we include this as a variable the coefficient is 3.7 bpm, however 
if we exclude it from the analysis the coefficient increases to 7.7 bpm (p<0.001). 
We believe 7.7 bpm is the true result as it shows the full drop in heart rate from 
the pre VM heart rate to post VM rate, showing the full level of vagal tone. In 
terminating SVT it is the vagal tone that terminates SVT not just the lowering of 
heart rate. This is part of the physiology behind the VM and is represented by a 
Valsalva ratio of 1.63. The Valsalva ratio has been shown to be a good predictor 
for the termination of SVT. The larger the vagal tone, the higher the chance of 
terminating SVT; therefore the pre VM heart rate should not be included as a 
variable. (37)  
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The Mehta study shows that a Valsalva ratio of >1.3 was very likely to terminate 
AVRT - 93% of participants terminated SVT on two out of three occasions, 
whereas with AVNRT this was shown to be less effective, only terminating 33%. 
(37) However this may be due to Mehta’s method of creating the Valsalva ratio 
and not measuring phase two which is where the majority of retrograde 
terminations occur. (34)  We included phase two within our measurement if any 
bradycardic response appeared there. The Mehta study had a higher termination 
rate than otherwise seen, though their Valsalva ratios peaked at 1.45 and both 
our ratios are much higher than this. This may indicate greater efficacy of our 
manoeuvres and the VAD.  
 
The VAD did not perform quite as well as the manometer with the difference in 
drop of heart rate just reaching statistical significance. This coefficient (1.9 bpm 
including pre VM heart rate as a confounding factor) was less than our previously 
stated clinically meaningful difference of 4bpm (which was excluded from the 95% 
confidence interval). It is debateable whether this would affect cardioversion rates 
in practice. In our second analysis, which excluded the interaction of having a 
higher pre VM heart rate, the results changed very slightly creating a coefficient 
of 2.0, however the difference now becomes insignificant (p=0.06). This is 
important as there are modifications we can apply to the VAD to make it more 
efficient, which means it has the potential to be at least as efficacious as the 
manometer.  
 
The Valsalva ratio of the VAD group is 1.52 compared to 1.59 of the manometer 
group, so, according to previous research the VAD should be effective in the 
termination of SVT. The benefit of having a small handheld device which is easy 
to use, by doctors, paramedics and patients, should give the VAD advantages 
over the manometer. The VAD should give a greater chance of termination from 
VM because the earlier a VM is carried out, the more effective it is. (6) An 
Australian paper showed that 92.8% of emergency doctors were unable to carry 
out a valid VM. (68) The VAD will also act as an aide-memoire for the modified 
VM and encourage its use in everyday practice.  
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The VAD was associated with significantly shorter strain duration than the 
manometer. Participants achieved an average strain duration of one second less 
with the VAD compared to the manometer. This is likely to be a result of the VAD’s 
air leak causing participants to prematurely run out of breath. A small leak is 
thought important to ensure that the required intrathoracic pressure is used 
instead of oral pressure. (27). Anecdotally it was more noticeable in female 
participants who have a lower lung functional residual capacity ran out of breath 
faster, which supports the theory that this leak was the cause for the reduced 
strain duration observed. This degree of leak and shorter duration of VM strain 
might account for the device’s marginally reduced effect on heart rate. This has 
been fed back to the manufacturer to consider refinements to the design.    
 
This study’s aim was to show a benefit of the VAD over the manometer, not a 
non-inferiority study. A non-inferiority study would show whether the manometer 
was the same as the VAD. A non-inferiority study requires many more people, 
but we believe it would show the VAD was not inferior to the manometer. This is 
because the results between the VAD and the manometer are very similar and 
with a small or no significance between them. We believe this difference will 
decrease in a non-inferiority study.  
The aim of this study was to explore the potential benefit of the VAD over the 
manometer. It was not a non-inferiority study, as this this requires many more 
participants. We believe that, were this a non-inferiority study, the results would 
have indicated that the VAD is not inferior to the manometer, on the basis that 
the results were similar between the two methods. A formal study of this would 
be required to verify this belief.  
 
The device produced a mean pressure of strain similar to the manometer. 
Although the variation of pressures was greater than with the manometer, this 
was within a clinically appropriate range and much better than that seen with use 
of a syringe. (5)  Recording pressures was difficult due to the potential variability 
during the 15 seconds strain. The pressure recorded was the highest the 
participants were able to sustain for 5 seconds. The impact of measuring the 
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pressures achieved in this way could have introduced a bias into the study. It is 
not known how well this value correlates with the pressures achieved over the full 
15 seconds, and serial or continuous measurements would have been able to 
improve the validity of the findings. While this was not feasible in this study, 
follow-up analyses could make use of this suggestion to further expand our 
knowledge of this topic.  
 
Previously upright straining postures have been associated with a greater drop in 
blood pressure and therefore increased risk of syncope during straining; this 
complication was not seen in our study. This is consistent with previous trials 
assessing the modified VM. (2,55) Although there were no serious adverse 
events we had more non-serious adverse events than previously described. We 
believe this was because every participant was prompted after every strain for 
any possible side effect which may have increased participants’ likelihood of 
commenting on their side effects and especially things they would not have 
otherwise mentioned. There were similar numbers of non-serious adverse events 
exhibited within each group, with no significant difference but a trend towards a 
lower number of adverse events in the VAD group.  
 
The benefit of the VAD, with an aide memoire for the modified VM, is to hopefully 
see a reduction in the Emergency Department admissions of SVT as they will be 
cardioverted in the pre-hospital environment and left at home. We hope patients 
can have their own VADs to enable cardioversion at home. 
 
We conducted our study on mainly young patients with a slight preponderance of 
females. This is the demographic of the population with SVT. There is a second 
peak of incidence in older age, often in patients with associated co-morbidities 
and so consideration should also be given to repeating this study and assessing 
device performance in the older population.  
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Limitations 
This study has important limitations. We acknowledge that this study used healthy 
volunteers and not patients with SVT. The VAD needs to be tested on patients in 
SVT to prove its clinical effectiveness, at the moment we can only theorise the 
efficacy of the VAD. We also recognise that this is a single site study carried out 
in Exeter, with patients only from the surrounding area, so it is not fully 
representative of the country. A large proportion of our participants are university 
students so this may have an effect on our results as the VM is more effective in 
the younger population.   
 
Our primary outcome of measuring RR intervals and pre VM baseline is inherently 
inaccurate. However, we blinded the investigator to minimise observer bias and 
reduced it further by repeating with a different blinded investigator who was not a 
part of the research team. (8)  
 
Efforts were made to standardise the level of inspiratory effort preceding the 
expiratory strain made by subjects for all manoeuvres, however accurate control 
of this was not always possible. Hence, some error may have been introduced 
by this variable. (8)  
 
Recording pressures was difficult due to the potential variability over 15 seconds, 
so we measured the peak pressure held for a few seconds and had one 
investigator to record results to improve standardisation. The VAD’s pressures 
were observed to be highest at the beginning and dropped significantly at the 
end. This means the recorded pressures may be misleading of the pressure 
achieved for the full 15 seconds.  
 
The results and alignment with previous studies suggest that our method is 
reliable.  We examined similar studies previously reported, and our methodology 
is similar. We used advanced statistics to ensure the strength of our findings. 
Despite our limitations, we believe that our method and results are reliable. 
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Next stage 
We are looking at other modifications to the VAD to try to improve its patient 
friendliness. We want to make some modifications to the window showing 
where to blow. We will create some mockups and use a focus group to decide 
which is best. Our options are to create a window, so the marker appears if you 
blow to the correct pressure, or to have a green section to blow the marker to. 
We will assess whether it will work for people that are sight impaired.  
 
Planned future studies will assess the use of the VAD in clinical practice by 
ambulance services to see the effects of the VAD and the aide memoire 
(ClinicalTrials.gov registration no: NCT03514628). We created an aide memoir to 
demonstrate how to use the VAD for this study shown in figure 21. 
 
 
 
 
 
 
 
 
 
Figure 25 VAD aide memoire   
 
 
I am also in the process of publishing the above results in the Emergency Medicine 
Journal (EMJ). This follows my first publication in the Emergency journal shown in 
Appendix H. 
15 seconds 15 seconds 
Blow here 
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Conclusions 
The findings in this study contribute to evidence supporting the efficacy of a 
modified VM producing a greater drop in heart rate than the supine VM. This 
confirms a physiological advantage (having a greater vagal response) with no 
increased risk of side effects and recommends the routine use of the modified 
VM. 
 
The VAD was shown to safely generate the recommended VM strain with 
equivalent pressure to the manometer. Some simple modifications may enable 
the recommended duration of strain and the full effect to be achieved, as currently 
the manometer generates a slightly greater drop in heart rate than the VAD. 
However the VAD’s benefits should outweigh this difference. The VAD’s 
performance in patients with SVT remains to be tested.  
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Appendix A – Good Clinical Practice eLearning 
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Appendix B – Ethical Approval 
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Appendix C – Screening Protocol 
 
Screening protocol 
 
Date of screening …………………………………………………… 
Participant screened:……………………………………… ……………………… 
Signature. …………………………………………………………………………… Date …………………………………………… 
In the event of medical concerns on the day of screening which the research 
nurses deem require urgent attention: For advice please contact Dr Appelboam. 
In the event of a medical emergency redirect participants to the emergency 
department or call 999.  
If participants have immediate concerns about their health and well-being they 
should contact health services as they normally would, through calling NHS 111 
or attending the emergency department/calling 999 if it is a medical emergency. 
 
 Please assure participants of the confidentiality of their answers, within the 
research study team. 
 Please advise participants cannot participate if they have consumed alcohol or 
a stimulant drug within 24 hours or caffeinated drinks within 6 hours. 
 CONSENT SIGNED?   Y/N 
 
 Date of Birth   
  
 
 Alcohol or stimulant drug in last 24 
hours 
 
 
 
 Caffeinated drinks in last 6 hours 
 
 
 Gender  
 Smoker – if yes how many for how long 
 
 
 
 Ask participants to name any medication they are taking, dose and frequency. 
Please list here: 
 
 
 
 Ask participants if and of the following health conditions apply now or ever 
have in the past  
Could they be pregnant? (females) Y / N  
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Structural cardiac abnormalities Y / N  
Any cardiac murmurs (Aortic stenosis) Y / N  
Cardiac arrhythmias Y / N  
Heart failure Y / N  
Other heart problems Y / N  
Respiratory disease (lung) Y / N  
Hyperthyroidism Y / N  
Vasculitis Y / N  
Retinopathy Y / N  
Glaucoma Y / N  
Family history of sudden death Y / N  
Unable to lie flat, or have legs raised greater than 45 
degrees. E.g. prosethic hip 
Y / N  
 
If the participant is unsure about whether any of the above apply please write notes in 
the right hand column  
 
 
 
 
 
 
 
 
 Ask participants to name any other past medical history. Please list here: 
 
 
 
 
 Vital signs (record these after the questionnaire has been completed): 
 
 
 
Observations Values Normal Ranges  
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1. Heart Rate Bpm <100 Bpm 
2. Respiratory Rate  11-20 
3. Oxygen saturations % >96% 
4. Blood Pressuren 
(systolic >100) 
 >100/60 systolic 
5. Respiratory Exam   breath sounds 
normal/expansion 
6. Cardiac Exam   heart sounds and rhythm 
 
7. ECG   Regular sinus rhythm, 
narrow QRS complexes, no 
signs of ventricular 
hypertrophy or ischaemia 
 
 Anything observed (irregular heartbeat, looks in anyway unwell)? Other 
comments 
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Appendix D – Standardised Instructions 
Standardised instructions for doing 
procedure 
 
There will be a total of 4 manoeuvres and your first one is –  
In between each manoeuvre you will have two minutes after each repositioning 
to rest and allow your heart rate to return to normal and at least 3 minutes 
between each manoeuvre. 
 
For the first 15 seconds, just sit and relax and I will count down to your first 
blow. Note if you run out of breath do not repeat the strain we will continue to 
the next part. We ask you to take a breath before each manoeuvre to ensure 
you have enough breath to complete it. 
 
Manoeuvre 1 - Supine VM using manometer 
 You will be laid flat and asked to blow into the manometer at a pressure 
of 40mmHg (marked on machine) for 15 seconds, then continue to lie still for 
the next 15 seconds 
 
Manoeuvre 2 - Supine VM using device 
 You will be laid flat and asked to blow into the device aiming for a 
pressure of 55 (green zone) in one breath for 15 seconds, then continue to lie 
still for the next 15 seconds 
 
Manoeuvre 3 - Modified VM using manometer 
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 You will be laid at 45 degree angle and asked to blow into the 
manometer at a pressure of 40mmHg (marked on machine) for 15 seconds. As 
soon as the 15s are over you need to completely relax and allow yourself to be 
laid flat and have your legs raised to a 45 degree angle, then continue to lie still 
for the next 15 seconds 
 
Manoeuvre 4 - Modified VM using device 
 You will be sat at a 45-degree angle and asked to blow into the device 
aiming for a pressure of 55 (green zone) in one breath for 15 seconds. As soon 
as the 15s are over you need to completely relax and allow yourself to be laid 
flat and have your legs raised to a 45 degree angle, then continue to lie still for 
the next 15 seconds  
 
It is important for all the manoeuvres that you get to appropriate pressure as 
soon as possible and try to hold it for the full 15 seconds. Note if you run out of 
breath do not take another breath but relax and lie still.  
 
Device – the device will sometimes stop making a noise or the red line stop 
moving but do not worry and continue with the strain. The device has four holes 
in the top so is often harder to create the pressure, for the full 15 seconds so try 
and take enough breath to complete the strain. 
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Appendix E – Duration of Strain 
Time grouped into <15 and 15.  No-one went over 15, so this is essentially “did 
they achieve 15 seconds, yes or no”. 
With manometer:   With new device: 
 
Overall: 
 
So ability to achieve 15 seconds is not affected by type of VM, not for 
manometer nor for new device. 
 
  
                  2.00      98.00      100.00 
     Total           3        147         150 
                                             
                  1.33      98.67      100.00 
  Modified           1         74          75 
                                             
                  2.67      97.33      100.00 
    Supine           2         73          75 
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Appendix F – Duration of strain in VAD and Manometer 
With manometer: 
 
 
 
With new device: 
 
                  2.00      98.00      100.00 
     Total           3        147         150 
                                             
                  1.33      98.67      100.00 
  Modified           1         74          75 
                                             
                  2.67      97.33      100.00 
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                     (s))
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Overall: 
 
 
 
So ability to achieve 15 seconds is not affected by type of VM, not for 
manometer nor for new device. 
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Appendix G – Raw Data 
Baselinemm PostVMmm Pre_Hrate Post_Hrate Diff_Hrate Ratio_Hrate Type_VM Type_Device 
163.5 20.5 76.72634 71.42857 5.297768 1.074169 Supine Manometer 
180 24 83.10249 75 8.102493 1.108033 Modified New Device 
156 25 60.12024 53.57143 6.548809 1.122244 Modified New Device 
159 22.5 81.52174 71.42857 10.09316 1.141304 Modified New Device 
177 24.5 96.15385 83.33334 12.82051 1.153846 Supine New Device 
200.5 32.5 77.12082 66.66666 10.45415 1.156812 Supine Manometer 
185 27 83.33334 71.42857 11.90476 1.166667 Modified Manometer 
199 29.5 89.82036 76.92308 12.89728 1.167665 Modified Manometer 
194.5 29 79.78723 68.18182 11.60542 1.170213 Modified New Device 
213.5 34 70.25761 60 10.25761 1.17096 Supine New Device 
206.5 26 60.60606 51.72414 8.881924 1.171717 Supine Manometer 
211.5 39 84.26966 71.42857 12.84109 1.179775 Modified Manometer 
161 23.5 80.64516 68.18182 12.46335 1.182796 Supine New Device 
155.5 21 75.37688 62.5 12.87688 1.20603 Modified New Device 
155 24 85.22727 69.76744 15.45983 1.221591 Modified Manometer 
156.5 28 70.92199 57.69231 13.22968 1.229315 Supine Manometer 
193 21 73.89162 60 13.89162 1.231527 Supine New Device 
185 24.5 81.08108 61.22449 19.85659 1.324324 Modified New Device 
194 27 62.63048 50.84746 11.78302 1.231733 Supine Manometer 
203 25 108.6957 88.23529 20.46037 1.231884 Supine New Device 
122 21 84.26966 68.18182 16.08784 1.235955 Modified Manometer 
146 25.5 80.64516 65.21739 15.42777 1.236559 Supine Manometer 
125 25.5 59.88024 48.3871 11.49314 1.237525 Supine New Device 
170 21.5 74.44169 60 14.44169 1.240695 Supine New Device 
247.5 29 88.75739 71.42857 17.32882 1.242603 Modified Manometer 
234 28 64.10256 53.57143 10.53113 1.196581 Modified New Device 
214.5 34 69.93007 44.11765 25.81242 1.585082 Modified Manometer 
250.5 31 79.5756 63.82979 15.74581 1.246684 Supine Manometer 
129.5 23 76.72634 61.22449 15.50185 1.253197 Supine Manometer 
144 21 91.74312 73.17073 18.57239 1.253823 Modified New Device 
130.5 30 52.35602 41.66667 10.68935 1.256544 Supine New Device 
127 22 66.22517 52.63158 13.59359 1.258278 Supine New Device 
193 27 72.63923 57.69231 14.94692 1.25908 Modified Manometer 
187.5 28.5 60.97561 48.3871 12.58851 1.260163 Supine New Device 
214 35 88.23529 69.76744 18.46785 1.264706 Supine New Device 
215 33 79.15567 62.5 16.65567 1.266491 Supine New Device 
140 25 85.22727 66.66666 18.56061 1.278409 Supine New Device 
139 22.5 80 62.5 17.5 1.28 Supine Manometer 
173 25.5 80 62.5 17.5 1.28 Supine New Device 
142.5 32.5 105.2632 46.15385 59.10931 2.280702 Modified New Device 
158 21.5 94.93671 69.76744 25.16927 1.360759 Modified New Device 
183.5 24.5 80 62.5 17.5 1.28 Supine Manometer 
163 26 76.92308 60 16.92308 1.282051 Supine Manometer 
179 24 62.1118 48.3871 13.7247 1.283644 Modified New Device 
133 28 81.96722 63.82979 18.13743 1.284153 Supine New Device 
142.5 28 81.96722 63.82979 18.13743 1.284153 Modified Manometer 
148 22 70.25761 54.54546 15.71216 1.288056 Supine Manometer 
139.5 24.5 63.42495 49.18033 14.24462 1.289641 Supine New Device 
141 22.5 69.12442 53.57143 15.55299 1.290322 Modified Manometer 
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146 29 80.86253 62.5 18.36253 1.293801 Modified New Device 
151 27.5 59.76096 46.15385 13.60711 1.294821 Modified New Device 
195.5 21 82.87292 63.82979 19.04314 1.298342 Modified New Device 
153 22 88.75739 68.18182 20.57558 1.301775 Modified Manometer 
169 22 78.53403 60 18.53403 1.308901 Supine Manometer 
157.5 22.5 78.94736 60 18.94736 1.315789 Supine New Device 
176.5 24 82.41758 62.5 19.91758 1.318681 Supine New Device 
237.5 33.5 79.15567 60 19.15567 1.319261 Supine New Device 
215 33 76.14214 57.69231 18.44983 1.319797 Modified New Device 
233.5 36 76.14214 57.69231 18.44983 1.319797 Supine Manometer 
187 38 82.64463 62.5 20.14463 1.322314 Supine New Device 
207 30.5 96.77419 73.17073 23.60346 1.322581 Supine Manometer 
202.5 32 74.07407 46.875 27.19907 1.580247 Supine Manometer 
205 28.5 92.30769 69.76744 22.54025 1.323077 Supine Manometer 
182 27 92.59259 69.76744 22.82515 1.32716 Supine New Device 
138 17 75.18797 56.60378 18.5842 1.328321 Supine New Device 
122 22 75.18797 56.60378 18.5842 1.328321 Modified New Device 
144 25 83.10249 62.5 20.60249 1.32964 Modified Manometer 
127.5 27 79.78723 60 19.78723 1.329787 Modified Manometer 
216 35.5 78.32898 58.82353 19.50545 1.331593 Supine New Device 
237 36 83.33334 62.5 20.83334 1.333333 Supine New Device 
237 34 83.79888 62.5 21.29888 1.340782 Supine Manometer 
218 36 103.4483 76.92308 26.52519 1.344828 Supine Manometer 
138.5 21 122.449 90.90909 31.53989 1.346939 Supine Manometer 
162 21.5 96.46302 71.42857 25.03445 1.350482 Supine New Device 
159 25 59.76096 44.11765 15.64331 1.354582 Supine New Device 
184 28 92.59259 68.18182 24.41077 1.358025 Modified New Device 
123 24 84.98583 62.5 22.48583 1.359773 Supine Manometer 
180.5 45 91.46342 66.66666 24.79675 1.371951 Supine New Device 
175.5 25 85.95988 62.5 23.45988 1.375358 Supine Manometer 
185 46.5 82.87292 60 22.87292 1.381215 Supine New Device 
233.5 37.5 79.78723 57.69231 22.09492 1.382979 Modified Manometer 
253 35 59.28854 42.85714 16.43139 1.383399 Supine New Device 
216 36 62.89308 45.45454 17.43854 1.383648 Supine New Device 
193.5 41 86.7052 62.5 24.2052 1.387283 Modified New Device 
158.5 28.5 73.17073 52.63158 20.53915 1.390244 Modified New Device 
180 21 77.31959 55.55556 21.76403 1.391752 Supine Manometer 
186 22 75.94936 54.54546 21.40391 1.392405 Supine Manometer 
181 26 68.49315 49.18033 19.31282 1.392694 Supine New Device 
224.5 32 69.76744 50 19.76744 1.395349 Supine New Device 
217 41 73.52941 52.63158 20.89783 1.397059 Supine New Device 
200 43 77.72021 55.55556 22.16465 1.398964 Supine New Device 
238.5 33 82.41758 58.82353 23.59405 1.401099 Modified Manometer 
148 26 76.53061 54.54546 21.98515 1.403061 Modified New Device 
161 25.5 95.84665 68.18182 27.66483 1.405751 Modified Manometer 
148.5 25 105.6338 75 30.6338 1.408451 Supine New Device 
183 23.5 63.15789 44.77612 18.38177 1.410526 Supine Manometer 
174 23 86.20689 65.21739 20.9895 1.321839 Supine Manometer 
181 25 94.33962 66.66666 27.67296 1.415094 Modified Manometer 
174 25.5 88.49557 62.5 25.99557 1.415929 Modified New Device 
167.5 24 81.74387 57.69231 24.05156 1.416894 Supine New Device 
194.5 22.5 101.3513 71.42857 29.92278 1.418919 Supine New Device 
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190.5 27.5 88.75739 62.5 26.25739 1.420118 Modified New Device 
201.5 25 63.69427 44.77612 18.91815 1.422505 Supine Manometer 
177 27.5 97.08738 68.18182 28.90556 1.423948 Modified Manometer 
192 32 85.47009 60 25.47009 1.424501 Supine New Device 
235.5 33.5 66.81515 46.875 19.94015 1.42539 Supine Manometer 
246 31 76.53061 53.57143 22.95918 1.428571 Modified New Device 
249.5 31 97.4026 68.18182 29.22078 1.428571 Supine New Device 
194.5 35.5 95.2381 66.66666 28.57143 1.428572 Modified New Device 
213.5 33 85.95988 60 25.95988 1.432665 Modified New Device 
224 33 87.7193 61.22449 26.49481 1.432749 Modified Manometer 
186 31 89.55224 62.5 27.05224 1.432836 Modified New Device 
194 27 77.31959 55.55556 21.76403 1.391752 Supine New Device 
186.5 27.5 80.42896 54.54546 25.8835 1.474531 Modified New Device 
183.5 24.5 92.02454 61.22449 30.80005 1.503067 Modified Manometer 
196 29 76.53061 51.72414 24.80647 1.479592 Supine Manometer 
224 34 71.77033 50 21.77033 1.435407 Supine Manometer 
210 33 82.87292 57.69231 25.18062 1.436464 Supine Manometer 
182 37 98.03922 68.18182 29.8574 1.437909 Supine New Device 
204 28.5 86.45533 60 26.45533 1.440922 Supine New Device 
213.5 27.5 92.02454 63.82979 28.19475 1.441718 Supine New Device 
196 28 78.74016 54.54546 24.1947 1.44357 Modified Manometer 
221 36 65.78947 45.45454 20.33493 1.447369 Supine Manometer 
190.5 31.5 88.75739 61.22449 27.5329 1.449704 Modified New Device 
185.5 24 90.63444 62.5 28.13444 1.450151 Modified New Device 
195 25 63.29114 43.47826 19.81288 1.455696 Supine Manometer 
188 26 104.1667 71.42857 32.73809 1.458333 Supine New Device 
189.5 25 64.37769 44.11765 20.26004 1.459228 Supine New Device 
150 25 100 60 40 1.666667 Supine Manometer 
182 24 81.08108 55.55556 25.52552 1.459459 Modified New Device 
169 24 93.1677 63.82979 29.33791 1.459627 Modified Manometer 
159 27 94.33962 55.55556 38.78407 1.698113 Modified Manometer 
157.5 26 95.2381 65.21739 30.02071 1.460317 Supine New Device 
191.5 25.5 86.20689 58.82353 27.38337 1.465517 Modified Manometer 
171 24.5 66.96429 45.45454 21.50974 1.473214 Supine Manometer 
191 25 72.46377 49.18033 23.28344 1.47343 Supine New Device 
173 25.5 86.7052 58.82353 27.88167 1.473988 Supine Manometer 
127 23 86.7052 58.82353 27.88167 1.473988 Supine Manometer 
149 23 65.35947 44.11765 21.24183 1.481481 Modified Manometer 
174.5 28 75.37688 50.84746 24.52943 1.482412 Supine New Device 
156 18 80.86253 54.54546 26.31708 1.48248 Modified Manometer 
154.5 22 82.41758 55.55556 26.86202 1.483516 Supine New Device 
162 22 101.3513 68.18182 33.16953 1.486487 Supine New Device 
162.5 21.5 84.26966 56.60378 27.66589 1.488764 Modified New Device 
155 36 67.72009 45.45454 22.26555 1.489842 Supine Manometer 
163.5 32.5 77.12082 51.72414 25.39668 1.491003 Supine New Device 
138 30 64.93507 43.47826 21.45681 1.493507 Supine New Device 
215 30 72.28915 48.3871 23.90206 1.493976 Supine New Device 
155 34 96.77419 44.11765 52.65655 2.193548 Modified New Device 
167.5 30.5 88.23529 58.82353 29.41176 1.5 Modified New Device 
187.5 24 94.63722 62.5 32.13722 1.514196 Modified New Device 
162.5 25 108.3032 71.42857 36.87467 1.516245 Modified Manometer 
128.5 28 66.96429 44.11765 22.84664 1.517857 Supine Manometer 
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157.5 23 70.09346 46.15385 23.93961 1.518692 Supine Manometer 
148 29 80 52.63158 27.36842 1.52 Modified New Device 
142 36 81.52174 53.57143 27.95031 1.521739 Supine Manometer 
180 29 83.33334 54.54546 28.78788 1.527778 Modified New Device 
169 28.5 88.23529 57.69231 30.54298 1.529412 Supine Manometer 
178 26.5 69.76744 45.45454 24.3129 1.534884 Supine Manometer 
165.5 32 69.76744 45.45454 24.3129 1.534884 Modified New Device 
226.5 28.5 92.30769 60 32.30769 1.538462 Supine New Device 
241.5 31 88.75739 57.69231 31.06509 1.538462 Supine Manometer 
240 29 62.5 51.72414 10.77586 1.208333 Supine Manometer 
249 33 60.24096 45.45454 14.78642 1.325301 Modified Manometer 
188 25 64.23983 41.66667 22.57316 1.541756 Supine New Device 
197 26 100.6711 65.21739 35.45375 1.543624 Modified New Device 
219 30.5 96.77419 62.5 34.27419 1.548387 Supine Manometer 
228 33 105.6338 68.18182 37.45199 1.549296 Supine Manometer 
167 19.5 94.93671 61.22449 33.71222 1.550633 Modified Manometer 
180.5 20 68.49315 44.11765 24.3755 1.552511 Supine Manometer 
195.5 24.5 84.74577 54.54546 30.20031 1.553672 Modified New Device 
187.5 24 99.66777 63.82979 35.83798 1.561462 Modified Manometer 
163 23.5 95.84665 61.22449 34.62216 1.565495 Modified New Device 
169.5 37.5 82.41758 52.63158 29.786 1.565934 Supine New Device 
161.5 25.5 100 63.82979 36.17021 1.566667 Modified New Device 
165 26.5 85.47009 54.54546 30.92463 1.566952 Supine New Device 
180.5 30.5 81.08108 51.72414 29.35694 1.567568 Supine Manometer 
181.5 22 82.64463 68.18182 14.46281 1.212121 Supine Manometer 
176 21.5 71.42857 45.45454 25.97403 1.571429 Modified New Device 
184 21 94.33962 60 34.33962 1.572327 Modified New Device 
173 24 92.87926 58.82353 34.05573 1.578947 Supine Manometer 
187.5 24 107.9137 68.18182 39.73185 1.582734 Supine New Device 
189.5 24 93.1677 58.82353 34.34417 1.583851 Supine Manometer 
178 21 95.5414 60 35.5414 1.592357 Supine New Device 
173 23 86.7052 65.21739 21.48781 1.32948 Supine New Device 
192 25.5 78.125 58.82353 19.30147 1.328125 Supine Manometer 
199 24 92.02454 57.69231 34.33223 1.595092 Modified Manometer 
199 26.5 75.37688 56.60378 18.77311 1.331658 Modified Manometer 
144 28.5 106.383 66.66666 39.71632 1.595745 Modified Manometer 
132 28 96.15385 60 36.15385 1.602564 Supine Manometer 
151 27 85.95988 53.57143 32.38845 1.604584 Supine New Device 
185 29 64.23983 40 24.23983 1.605996 Supine Manometer 
188.5 41 90.90909 56.60378 34.30531 1.606061 Modified New Device 
165 30 83.33334 51.72414 31.6092 1.611111 Modified Manometer 
174 31 98.68421 61.22449 37.45972 1.611842 Supine New Device 
187 34.5 107.9137 66.66666 41.247 1.618705 Modified Manometer 
229.5 34 83.79888 51.72414 32.07475 1.620112 Supine Manometer 
225.5 30.5 66.51884 49.18033 17.33852 1.35255 Modified New Device 
242 33.5 61.98347 44.91018 17.07329 1.380165 Supine Manometer 
196 33 74.44169 45.45454 28.98714 1.637717 Supine New Device 
155 20.5 74.81297 46.15385 28.65912 1.620948 Supine Manometer 
110.5 36 97.4026 60 37.4026 1.623377 Supine Manometer 
148 21 67.87331 41.66667 26.20664 1.628959 Supine New Device 
131.5 28 70.09346 42.85714 27.23632 1.635514 Modified Manometer 
122.5 16.5 72.46377 44.11765 28.34612 1.642512 Modified Manometer 
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152 25.5 69.44444 42.25352 27.19092 1.643518 Modified Manometer 
147.5 28 95.2381 57.69231 37.54579 1.650794 Modified New Device 
156.5 22 68.80734 41.66667 27.14067 1.651376 Modified New Device 
164 22.5 78.74016 47.61905 31.12111 1.653543 Modified Manometer 
180.5 24 112.782 68.18182 44.60014 1.654135 Modified New Device 
197 26 69.44444 41.66667 27.77777 1.666667 Modified New Device 
169 24.5 78.125 46.875 31.25 1.666667 Modified Manometer 
115.5 25.5 80.64516 48.3871 32.25807 1.666667 Modified New Device 
145.5 24.5 98.68421 58.82353 39.86068 1.677632 Supine New Device 
150 27.5 101.0101 60 41.0101 1.683502 Modified Manometer 
161.5 30.5 84.26966 50 34.26966 1.685393 Modified Manometer 
255 34 58.82353 44.11765 14.70588 1.333333 Supine New Device 
264.5 36.5 56.71077 41.09589 15.61488 1.379962 Supine Manometer 
244 33 61.47541 45.45454 16.02087 1.352459 Modified Manometer 
220 35.5 68.18182 42.25352 25.9283 1.613636 Modified New Device 
174.5 24 88.75739 52.63158 36.12581 1.68639 Supine New Device 
169.5 24 83.10249 49.18033 33.92216 1.689751 Supine New Device 
176 22.5 87.46355 51.72414 35.73942 1.690962 Modified Manometer 
186 32.5 101.6949 60 41.69492 1.694915 Modified New Device 
150.5 23.5 72.9927 42.85714 30.13556 1.703163 Modified New Device 
173.5 25 131.5789 76.92308 54.65587 1.710526 Supine New Device 
169 26 95.5414 55.55556 39.98585 1.719745 Modified New Device 
156.5 24.5 122.9508 71.42857 51.52225 1.721311 Modified New Device 
207 34 106.0071 61.22449 44.78257 1.731449 Supine Manometer 
239.5 29.5 118.1102 68.18182 49.92842 1.732283 Modified New Device 
199 37 104.1667 60 44.16666 1.736111 Supine Manometer 
251 34 102.7397 58.82353 43.91619 1.746575 Modified Manometer 
214 32.5 80.64516 46.15385 34.49132 1.747312 Modified Manometer 
162.5 41 107.5269 61.22449 46.30239 1.756272 Modified Manometer 
192.5 40 101.3513 57.69231 43.65904 1.756757 Modified New Device 
231 30.5 118.1102 66.66666 51.44357 1.771654 Modified Manometer 
251 32.5 88.75739 50 38.75739 1.775148 Modified Manometer 
184 34.5 115.8301 65.21739 50.61272 1.776062 Supine Manometer 
286.5 36 86.20689 48.3871 37.8198 1.781609 Supine New Device 
293 34.5 51.19454 43.47826 7.716278 1.177474 Supine Manometer 
157 25 107.1429 60 47.14286 1.785714 Supine New Device 
186 37 99.33775 55.55556 43.78219 1.788079 Supine New Device 
211.5 26 95.84665 53.57143 42.27522 1.789137 Modified New Device 
163 30 94.63722 52.63158 42.00564 1.798107 Modified New Device 
174.5 25 122.9508 68.18182 54.769 1.803279 Modified New Device 
181.5 24 118.1102 65.21739 52.89285 1.811024 Modified Manometer 
188 23.5 79.78723 63.82979 15.95744 1.25 Modified Manometer 
190.5 33 78.74016 45.45454 33.28561 1.732283 Supine Manometer 
154 22 108.6957 60 48.69566 1.811594 Modified New Device 
170 26 90.90909 50 40.90909 1.818182 Modified New Device 
158.5 24 89.55224 49.18033 40.37191 1.820896 Modified Manometer 
159.5 31.5 99.33775 54.54546 44.79229 1.821192 Supine New Device 
165.5 24 77.12082 42.25352 34.8673 1.825193 Modified Manometer 
167.5 24 89.55224 62.5 27.05224 1.432836 Modified Manometer 
187.5 25.5 80 58.82353 21.17647 1.36 Supine Manometer 
176 25 85.22727 60 25.22727 1.420455 Supine New Device 
207.5 35 100 54.54546 45.45454 1.833333 Supine New Device 
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231 34.5 92.02454 50 42.02454 1.840491 Modified Manometer 
221.5 33 70.92199 38.46154 32.46045 1.843972 Modified New Device 
186 35.5 80.21391 43.47826 36.73565 1.84492 Supine Manometer 
188 22 75.37688 40.54054 34.83635 1.859297 Modified New Device 
186 23 81.52174 43.47826 38.04348 1.875 Modified Manometer 
183 23.5 92.87926 49.18033 43.69893 1.888545 Modified Manometer 
190 25 69.12442 36.58537 32.53905 1.889401 Modified Manometer 
169 30 90.63444 46.875 43.75944 1.933535 Supine Manometer 
197.5 27.5 121.9512 62.5 59.45122 1.951219 Supine Manometer 
182 27 101.3513 51.72414 49.62721 1.959459 Supine Manometer 
170 25.5 105.2632 53.57143 51.69173 1.964912 Supine Manometer 
139.5 27.5 107.5269 54.54546 52.98142 1.971326 Supine Manometer 
139 22 94.04388 47.61905 46.42484 1.974921 Modified Manometer 
185.5 27.5 104.1667 52.63158 51.53508 1.979167 Modified New Device 
181 23.5 102.7397 51.72414 51.01559 1.986301 Modified New Device 
175.5 26.5 91.74312 46.15385 45.58927 1.987768 Supine Manometer 
196 40 80.64516 40.54054 40.10463 1.989247 Modified New Device 
178 34.5 103.4483 51.72414 51.72414 2 Supine Manometer 
188.5 31 107.9137 53.57143 54.34224 2.014388 Modified Manometer 
114 19.5 80.21391 39.47368 40.74022 2.032086 Modified Manometer 
133 22 82.41758 40.54054 41.87704 2.032967 Modified Manometer 
127 22.5 120 58.82353 61.17647 2.04 Supine Manometer 
142 22 88.49557 42.85714 45.63843 2.064897 Modified Manometer 
179 29 77.92208 37.5 40.42208 2.077922 Modified New Device 
180 27.5 112.782 53.57143 59.21052 2.105263 Modified New Device 
169.5 35 117.6471 55.55556 62.0915 2.117647 Modified Manometer 
205 31 77.51938 36.58537 40.93401 2.118863 Modified Manometer 
139 28 113.6364 53.57143 60.06493 2.121212 Modified Manometer 
152 24.5 114.0684 53.57143 60.49701 2.129277 Modified New Device 
150 23.5 75 34.88372 40.11628 2.15 Modified New Device 
145 19.5 108.6957 50 58.69566 2.173913 Modified New Device 
142 20 79.5756 36.58537 42.99023 2.175066 Modified Manometer 
145 29 92.02454 42.25352 49.77102 2.177914 Modified Manometer 
178 30 116.7315 53.57143 63.16008 2.178988 Modified New Device 
157 27 129.8701 58.82353 71.0466 2.207792 Modified New Device 
199.5 26.5 88.49557 40 48.49557 2.212389 Modified Manometer 
217 28 114.9425 50 64.94253 2.298851 Modified Manometer 
209 30 100 41.66667 58.33333 2.4 Modified Manometer 
199.5 26.5 83.10249 33.33333 49.76916 2.493075 Modified Manometer 
154 25 81.08108 32.25806 48.82301 2.513513 Modified New Device 
138 25 92.30769 36.58537 55.72233 2.523077 Modified Manometer 
182 28.5 105.6338 41.66667 63.96714 2.535211 Modified Manometer 
171.5 29 135.7466 41.66667 94.07994 3.257919 Modified Manometer 
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Appendix H – Letter to Editor – A Simple Device to Control 
Valsalva Manoeuvre Strain Pressure 
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Glossary 
Term Definition 
Cardioversion Return of heart rhythm back to normal rhythm. 
Carotid Sinus Massage Gentle massage of the carotid artery on the side of 
your neck for 5 seconds (type of vagal manoeuvres). 
Human Dive Reflex A physiological reflex to immersion that causes 
physiological changes to conserve oxygen (type of 
vagal manoeuvre). 
Manometer Pressure gauge often used to measure blood 
pressure. 
Modified VM Participants performed the strain in the semi-
recumbent position but immediately at the end of the 
strain, were laid flat and had their legs raised to 45° 
for 15 seconds. (2) 
Observational Trial A retrospective or prospective study which observes 
the natural course of events with or without a control 
group. (73) 
Randomised Controlled Trial Participants are randomly assigned to 2 (or more) 
groups, one group has a specific intervention with the 
other group having either a dummy intervention 
(placebo) or no intervention. Outcomes are accessed 
statistically. (73) 
Repeated Measures Trial Each participant is exposed to multiple conditions 
over time or under different conditions.  
Retrospective Study This study examines past exposure to a suspected 
risk factors for a disease or condition. (73) 
Supine VM Lying flat while completing a VM (for 15 seconds at 
pressure of 40mmHg). 
Supraventricular Tachycardia Abnormal rapid heart rate caused by electrical 
impulses originating above the heart’s ventricles. 
Systematic Review A review summarises the evidence on a clearly 
formulated review question according to a predefined 
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protocol, using systematic and explicit methods to 
identify, analyse and collate findings. (73) 
Termination of SVT SVT stops and the heart returns to normal rhythm.  
Vagal Manoeuvres A manoeuvre that stimulates the vagal nerve and 
causes a reflex bradycardia. 
VAD A purpose built device to create the correct pressure 
during a VM 
Valsalva Manoeuvre An exhalation against resistance, similar to blowing 
up a balloon. 
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